Attenuated strains of betacoronavirus

An attenuated betacoronavirus strain with specific mutations addresses the safety concerns of existing COVID-19 vaccines by providing a low-pathogenic, immunogenic vaccine effective against multiple SARS-CoV-2 strains, including variants.

JP7594686B2Active Publication Date: 2024-12-04THE RES FOUND FOR MICROBIAL DISEASES OFOSAKA UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023558098
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-08-24
Filing Date
2022-11-07
Publication Date
2024-12-04
Estimated Expiration
2042-11-07

AI Technical Summary

Technical Problem

Existing vaccines against COVID-19, such as genetic vaccines, have reported side effects like fever and thrombosis, necessitating the development of new vaccines with reduced virulence and improved safety profiles.

Method used

Development of an attenuated betacoronavirus strain with specific mutations, including temperature-sensitive and growth-reducing mutations, to create a vaccine with reduced pathogenicity and enhanced immunogenicity, utilizing a combination of substitution and deletion mutations in nonstructural, structural, and accessory proteins.

Benefits of technology

The attenuated strain exhibits low pathogenicity, effective immunogenicity, and broad-spectrum protection against various SARS-CoV-2 strains, including variants, with minimal side effects and stable attenuation properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594686000007
    Figure 0007594686000007
  • Figure 0007594686000008
    Figure 0007594686000008
  • Figure 0007594686000009
    Figure 0007594686000009
Patent Text Reader

Abstract

The purpose of the present invention is to provide a strain that is useful as a new betacoronavirus vaccine. A novel betacoronavirus, according to the present invention, having, in combination, a prescribed substitution mutation relating to temperature sensitivity, and a prescribed deletion mutation relating to attenuation, is found to be useful as a betacoronavirus vaccine strain having excellent attenuated characteristics.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an attenuated betacoronavirus strain. [Background technology]

[0002] The novel coronavirus (SARS-CoV-2) has caused a pandemic and is still a social problem. As a vaccine against this infection, Sputnik V (Non-Patent Document 1), an adenovirus vector vaccine approved in Russia, has been approved, followed by adenovirus vector vaccines and gene vaccines such as mRNA vaccines, and vaccinations are being promoted around the world. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] THE LANCET, VOLUME 396, ISSUE 10255, P887-897, SEPTEMBER 26,2020 Summary of the Invention [Problem to be solved by the invention]

[0004] However, genetic vaccines are next-generation vaccines that are different from conventional vaccines, and side effects such as fever and thrombosis have been reported. For this reason, it is important to continue developing new vaccines.

[0005] Therefore, an object of the present invention is to provide a strain that is useful as a new betacoronavirus vaccine. [Means for solving the problem]

[0006] As a result of intensive research, the present inventors have found that a novel betacoronavirus having a combination of a specific substitution mutation related to temperature sensitivity and a specific deletion mutation related to reduced proliferation or other attenuation as a specific mutation related to attenuation is useful as a betacoronavirus vaccine strain with excellent attenuation. The present invention was completed based on this finding and through further research. That is, the present invention provides the following aspects of the invention.

[0007] Item 1. A nonstructural protein having the following mutation (b), a combination of mutations (e) and (f), and / or mutation (h); A structural protein, an accessory protein and / or a non-structural protein having the following mutations (n), (о) and / or (r): Attenuated strains of betacoronavirus, including: (b) a mutation in NSP3 at an amino acid residue corresponding to leucine at position 445 of the amino acid sequence set forth in SEQ ID NO:1; (e) a mutation in NSP14 at the amino acid residue corresponding to glycine at position 248 of the amino acid sequence set forth in SEQ ID NO:2; (f) a mutation in NSP14 of the amino acid residue corresponding to glycine at position 416 of the amino acid sequence set forth in SEQ ID NO:2; (h) a mutation in NSP16 of the amino acid residue corresponding to valine at position 67 of the amino acid sequence set forth in SEQ ID NO:3; (n) loss-of-function mutation of ORF8, (o) a deletion in the spike of an amino acid sequence corresponding to positions 681 to 684 of the amino acid sequence shown in SEQ ID NO: 4; (r) Deletion of the amino acid sequence corresponding to positions 32 to 39 of the amino acid sequence shown in SEQ ID NO:8 in NSP1. Item 2. The attenuated virus strain according to Item 1, wherein four mutations or combinations of mutations are selected from the six mutations or combinations of mutations: the mutation (b), the combination of the mutations (e) and (f), the mutation (h), the mutation (n), the mutation (о), and the mutation (r). Item 3. The attenuated virus strain according to Item 1 or 2, wherein one or two mutations or combinations of mutations are selected from the three mutations or combinations of mutations: the mutation in (b), the combination of the mutations in (e) and (f), and the mutation in (h). Item 4. The attenuated virus strain according to any one of Items 1 to 3, wherein the structural protein further comprises the following mutations (p) and / or (q): (p) a mutation in spike comprising a deletion of the amino acid sequence corresponding to positions 679 to 680 and positions 685 to 686 of the amino acid sequence shown in SEQ ID NO: 4; (q) A mutation in the amino acid residue in spike corresponding to valine at position 687 of the amino acid sequence shown in SEQ ID NO:4. Item 5. The attenuated virus strain according to Item 4, comprising a combination of the mutations (e) and (f) above and the following mutation (g): (g) A mutation in the amino acid residue in NSP14 corresponding to alanine at position 504 in the amino acid sequence set forth in SEQ ID NO:2. Item 6. An attenuated betacoronavirus strain described in Item 4 or 5, wherein the mutation (n) is a deletion of an amino acid sequence corresponding to the amino acid sequence encoded by the base sequence shown in SEQ ID NO: 7. Item 7. The attenuated virus strain according to any one of Items 1 to 6, wherein the mutation (b) is a substitution with phenylalanine, the mutation (e) is a substitution with valine, the mutation (f) is a substitution with serine, and the mutation (h) is a substitution with isoleucine. Item 8. The attenuated virus strain according to any one of Items 4 to 7, wherein the mutation (q) is a substitution with isoleucine. Item 9. The attenuated virus strain described in any one of Items 1 to 8, wherein the betacoronavirus is a SARS-CoV-2 virus. Item 10. A live attenuated vaccine comprising the attenuated virus strain according to any one of Items 1 to 9. Item 11. The live attenuated vaccine according to Item 10, which is administered intranasally. Item 12. The live attenuated vaccine according to Item 10, which is administered intramuscularly, subcutaneously or intradermally. Effect of the Invention

[0008] According to the present invention, a strain useful as a new betacoronavirus vaccine is provided. [Brief description of the drawings]

[0009] [Figure 1] This shows how to make SARS-CoV-2 temperature sensitive. [Diagram 2] The results of confirming the temperature sensitivity of SARS-CoV-2 (CPE image) are shown. [Figure 3A] The results of mutation analysis of each virus strain are shown. [Figure 3B] The CPE image of a possible reversion mutant of a temperature-sensitive strain (A50-18 [Reference Example]) is shown. [Figure 3C] The CPE image of a possible reversion mutant of a temperature-sensitive strain (A50-18 [Reference Example]) is shown. [Figure 3D] The results of confirming the temperature sensitivity of a recombinant virus into which a mutation was introduced in a temperature-sensitive strain (A50-18 [Reference Example]) are shown. [Figure 3E] The results of confirming the temperature sensitivity of a recombinant virus into which a mutation was introduced in a temperature-sensitive strain (A50-18 [Reference Example]) are shown. [Figure 4A] The results of growth analysis of a temperature-sensitive strain (A50-18 [Reference Example]) are shown. [Figure 4B] The results of growth analysis of a temperature-sensitive strain (A50-18 [Reference Example]) are shown. [Diagram 5] 1 shows changes in body weight of hamsters infected with a temperature-sensitive strain (A50-18 [Reference Example]). [Figure 6] 1 shows changes in body weight of hamsters infected with a temperature-sensitive strain (A50-18 [Reference Example]). [Figure 7] The virus amount in the lungs or nasal washings of hamsters infected with a temperature-sensitive strain (A50-18 [Reference Example]) is shown. [Figure 8] This shows an image of the lungs of a hamster infected with a temperature-sensitive strain (A50-18 [Reference Example]). [Figure 9] 1 shows the results of histological analysis of the lungs of hamsters infected with a temperature-sensitive strain (A50-18 [Reference Example]). [Figure 10] 1 shows lung histological analysis (HE staining and IHC staining) of a hamster infected with a temperature-sensitive strain (A50-18 [Reference Example]). [Figure 11] This shows changes in body weight in hamsters reinfected with a temperature-sensitive strain (A50-18 [Reference Example]). [Figure 12] This shows changes in body weight of hamsters after infection with a temperature-sensitive strain (A50-18 [Reference Example]). [Figure 13] The neutralizing antibody titer of serum from hamsters that recovered after infection with a temperature-sensitive strain (A50-18 [Reference Example]) is shown. [Figure 14] A method for temperature-sensitizing SARS-CoV-2 (G-L50 series [Example]) is shown. [Figure 15] The results of confirming the temperature sensitivity of SARS-CoV-2 (G to L50 series [Example]) (CPE image) are shown. [Figure 16A] The results of mutation analysis of additional isolated strains (H50-11, L50-33, L50-40 [Example]) are shown. [Figure 16B] 1 shows a CPE image of a temperature-sensitive strain (H50-11 [Example]) that may have undergone reversion mutation. [Figure 16C] 1 shows CPE images of temperature-sensitive strains (L50-33, L50-40 [Example]) that may have reverse mutations. [Figure 17] The deletions in the nucleotide sequences found in relation to the temperature-sensitive strains (H50-11, L50-33, L50-40 [Example]) are shown. [Figure 18] A schematic diagram of the deletion of the base sequence shown in Figure 17 and the deletion of the amino acid sequence encoded thereby is shown. [Figure 19] 1 shows the results of growth analysis of temperature-sensitive strains (H50-11, L50-33, and L50-40 [Example]). [Figure 20] 1 shows changes in body weight of hamsters infected with temperature-sensitive strains (A50-18 [Reference Example], and H50-11, L50-33, and L50-40 [Examples]). [Figure 21]1 shows the lung weights of hamsters infected with temperature-sensitive strains (A50-18 [Reference Example], and H50-11, L50-33, and L50-40 [Examples]). [Figure 22] 1 shows the amount of virus in the lungs or nasal washings of hamsters infected with temperature-sensitive strains (A50-18 [Reference Example], and H50-11, L50-33, and L50-40 [Examples]). [Figure 23] 1 shows changes in body weight of hamsters reinfected with temperature-sensitive strains (A50-18 [Reference Example], and H50-11, L50-33, and L50-40 [Examples]). [Figure 24] 1 shows neutralizing antibody titers of hamster sera after infection with temperature-sensitive strains (A50-18 [Reference Example], and H50-11, L50-33, and L50-40 [Examples]). [Diagram 25] The neutralizing activity of a temperature-sensitive strain (A50-18 strain [reference example]) against SARS-CoV-2 mutant strains is shown. [Figure 26] 1 shows a comparison of immune induction ability depending on the administration route of a temperature-sensitive strain (A50-18 strain [Reference Example]). [Figure 27] A comparison of immune induction ability depending on the dose of a temperature-sensitive strain (A50-18 strain [Reference Example]) is shown. [Figure 28] The neutralizing activity of a temperature-sensitive strain (A50-18 strain [reference example]) against SARS-CoV-2 mutant strains is shown. [Figure 29] The neutralizing activity of a temperature-sensitive strain (A50-18 strain [reference example]) against SARS-CoV-2 mutant strains is shown. [Diagram 30] 1 shows CPE images during recovery culture after production of vaccine candidate strains 1 to 7 [Example]. [Figure 31A] 1 shows the temperature sensitivity evaluation of vaccine candidate strains 1 to 7 [Example]. [Figure 31B] 1 shows an evaluation of temperature sensitivity of the rTs-all strain [Example]. [Diagram 32] 1 shows the neutralizing antibody induction ability of vaccine candidate strains 1, 3, 4, 6, and 7 [Example] when administered at low titers and low doses. [Diagram 33]1 shows the results of an infection protection test after immunization with low-titer, low-dose vaccine candidate strain 7 [Example]. [Diagram 34] 1 shows the neutralizing antibody induction ability of vaccine candidate strains 2 and 5 [Examples] when administered at high titers and high doses. [Diagram 35] 1 shows the growth evaluation of vaccine candidate strain 2 [Example] at each temperature. [Diagram 36] 1 shows the results of a test on the persistence of humoral immunity induced by administration of vaccine candidate strain 2 [Example]. [Figure 37] 1 shows the results of a test of protection against infection by administration of vaccine candidate strain 2 [Example] (changes in body weight of infected hamsters). [Figure 38] 1 shows the results of examining reversion of virulence (presence or absence of CPE) during in vivo passage of vaccine candidate strain 2 [Example]. [Figure 39] 1 shows the results of an investigation into the reversion of virulence during in vivo passage of vaccine candidate strain 2 [Example] (viral RNA sequence extracted from each nasal wash). [Diagram 40] 1 shows the results of an investigation into reversion of virulence (body weight change) during in vivo passage of vaccine candidate strain 2 [Example]. [Diagram 41] 1 shows tissue damage evaluation (nasal cavity level 1) by vaccine candidate strain 2 [Example]. [Diagram 42] 1 shows tissue damage evaluation (nasal cavity level 2) by vaccine candidate strain 2 [Example]. [Diagram 43] 1 shows tissue damage evaluation (nasal cavity level 3) by vaccine candidate strain 2 [Example]. [Diagram 44] 1 shows tissue damage evaluation (lungs) by vaccine candidate strain 2 [Example]. [Diagram 45] 1 shows the neutralizing antibody titer induced by administration of vaccine candidate strain 2 [Example]. [Figure 46] 1 shows the results of a test of protection against infection by administration of vaccine candidate strain 2 [Example] (changes in body weight of infected hamsters). [Figure 47] 1 shows the neutralizing antibody titer induced by administration of vaccine candidate strain 2 [Example]. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] 1. Attenuated strains of betacoronavirus The attenuated betacoronavirus strain of the present invention is characterized in that it is a betacoronavirus having, as a specific mutation related to attenuation, a combination of a nonstructural protein having a specific substitution mutation related to temperature sensitivity, and a structural protein, accessory protein and / or nonstructural protein having a specific deletion mutation related to growth-reducing or other attenuation. Hereinafter, a specific substitution mutation related to temperature sensitivity will also be referred to as a "temperature-sensitive mutation", a specific deletion mutation related to growth-reducing ability will also be referred to as a "growth-reducing mutation", and a specific deletion mutation other than a growth-reducing mutation will also be referred to as a "other attenuating mutation".

[0011] In the present invention, "attenuated virulence" refers to a property that reduces the host pathogenicity of a virus. In addition, in the present invention, "temperature sensitivity" refers to a property that the proliferation ability is limited at human body temperature (so-called lower respiratory tract temperature) and that the proliferation ability is specific to low temperatures (typically lower than the upper respiratory tract temperature in humans). In addition, in the present invention, "proliferation-reducing ability" refers to a property that the proliferation ability is limited and that the property is not temperature-specific.

[0012] The attenuated betacoronavirus strain of the present invention not only exhibits efficacy as a vaccine by having the above-mentioned specific mutations related to attenuation, but also has a very low possibility of reversion to virulence because the substitution mutations are combined with deletion mutations that are unlikely to revert, significantly increasing its usefulness when applied to humans.

[0013] Morphologically, coronaviruses are spherical with a diameter of about 100 to 200 nm and have projections on their surface. Virologically, coronaviruses are classified into the order Nidovirales, subfamily Coronavirinae, and family Coronaviridae. Inside the lipid bilayer envelope, there is a genome of positive-sense single-stranded RNA wrapped around a nucleocapsid protein (hereinafter also referred to as "nucleocapsid" or "nucleocapsid"). On the surface of the envelope, spike protein (hereinafter also referred to as "spike" or "spike"), envelope protein (hereinafter also referred to as "envelope" or "envelope"), and membrane protein (hereinafter also referred to as "membrane" or "membrane") are arranged. The size of the viral genome is about 30 kb, the longest among RNA viruses. The nucleocapsid, spike, envelope, and membrane are structural proteins of coronaviruses. NSP1 to NSP16 are nonstructural proteins of coronaviruses. In addition, ORF7a, ORF7b, ORF8, etc. are accessory proteins of coronaviruses. In addition, accessory proteins can also be called accessory proteins.

[0014] Coronaviruses are classified into alpha, beta, gamma, and delta groups based on genetic characteristics. Coronaviruses that infect humans include four types of human coronaviruses that cause the common cold: human coronavirus 229E, OC43, NL63, and HKU-1; and the severe acute respiratory syndrome (SARS) coronavirus that emerged in 2002 and the Middle East respiratory syndrome (MERS) coronavirus that emerged in 2012, which cause severe pneumonia. Human coronavirus 229E and NL63 are classified into the alphacoronavirus genus, and human coronavirus OC43, HKU-1, SARS coronavirus, and MERS coronavirus are classified into the betacoronavirus genus.

[0015] SARS-CoV-2, classified as a SARS coronavirus, has been isolated and identified as the causative virus of the novel coronavirus disease that occurred in Wuhan in 2019. SARS-CoV-2 has repeatedly mutated from the initial Wuhan strain, and mutant strains such as strains detected in the UK, South Africa, and India have been found. It is possible that mutant strains that have not yet been detected and new mutant strains may occur in the future. In the present invention, the viruses included in the genus Betacoronavirus are not limited to the above-mentioned SARS-CoV-2 strain, but also include all other Betacoronaviruses (for example, other SARS-CoV-2 mutant strains and Betacoronaviruses other than SARS-CoV-2 that will be newly detected in the future, and recombinant viruses in which the spike protein of SARS-CoV-2 or Betacoronaviruses other than SARS-CoV-2 has been replaced with at least one spike protein of other SARS-CoV-2 and Betacoronaviruses other than SARS-CoV-2 (including viruses that will be newly detected in the future)).

[0016] The specific mutations related to the attenuation possessed by the attenuated betacoronavirus strain of the present invention are described based on Table 1 below. Mutation (b), a combination of mutations (e) and (f), and / or mutation (h), shown as "temperature-sensitive mutations" in Table 1, are substitution mutations, and are responsible mutations that contribute to imparting temperature sensitivity, which are essential for the attenuated betacoronavirus strain of the present invention. In other words, in the present invention, there are three types of temperature-sensitive mutations: "mutation (b)", "a combination of mutations (e) and (f)", and "mutation (h)". A typical attenuated betacoronavirus strain of the present invention has one or two of these three types of temperature-sensitive mutations. Mutations (n), (о) and / or (r) shown in Table 1 as "growth-reducing mutations" and "other attenuating mutations" are deletion mutations that are essential for the attenuated betacoronavirus strain of the present invention and are believed to contribute to imparting growth-reducing properties and other attenuation (in particular, mutation (r) is believed to contribute to imparting growth-reducing properties), and are mutations that express excellent attenuation in combination with a temperature-sensitive mutation. Mutations (a), (c), (d), (g), (i) to (m), (p), and (q) shown in Table 1 as "other mutations" are mutations that can be optionally contained in the attenuated betacoronavirus strain of the present invention, and the attenuated betacoronavirus strain of the present invention may or may not contain at least any of the other mutations.

[0017] [Table 1]

[0018] That is, the essential attenuating mutations possessed by the betacoronavirus of the present invention are the following mutations (b), a combination of mutations (e) and (f), and / or mutation (h), which are temperature-sensitive mutations; and the following mutations (n), (о) and / or (r), which are growth-reducing or other attenuating mutations. (b) a mutation in NSP3 at an amino acid residue corresponding to leucine at position 445 of the amino acid sequence set forth in SEQ ID NO:1; (e) a mutation in NSP14 at the amino acid residue corresponding to glycine at position 248 of the amino acid sequence set forth in SEQ ID NO:2; (f) a mutation in NSP14 of the amino acid residue corresponding to glycine at position 416 of the amino acid sequence set forth in SEQ ID NO:2; (h) a mutation in NSP16 of the amino acid residue corresponding to valine at position 67 of the amino acid sequence set forth in SEQ ID NO:3; (n) loss-of-function mutation of ORF8, (o) a deletion of amino acid residues corresponding to positions 681 to 684 of the amino acid sequence shown in SEQ ID NO: 4 in the spike; (r) Deletion of the amino acid sequence corresponding to positions 32 to 39 of the amino acid sequence shown in SEQ ID NO:8 in NSP1.

[0019] The mutation (n) above is acceptable as long as it causes the loss of function of ORF8, but preferably includes a deletion of an amino acid sequence corresponding to the amino acid sequence encoded by the base sequence shown in SEQ ID NO:7.

[0020] In a preferred embodiment of the present invention, from the viewpoint of controlling the level of temperature sensitivity to a preferred degree, one or two types of mutations or combinations of mutations are selected from the above-mentioned temperature-sensitive mutations (i.e., the three types of mutations or combinations of mutations: mutation (b), a combination of mutations (e) and (f), and mutation (h)).

[0021] In a preferred embodiment of the present invention, among the above-mentioned proliferation-reducing and other attenuating mutations, preferred examples include mutation (o) and mutation (r).

[0022] In a preferred embodiment of the present invention, from the viewpoint of achieving favorable attenuating toxicity while also achieving favorable immunogenicity, four mutations or combinations of mutations are selected from the six predetermined mutations related to attenuating toxicity (i.e., six mutations: mutation (b), a combination of mutations (e) and (f), mutation (h), mutation (n), mutation (o), and mutation (r)).

[0023] In addition to the essential mutations described above, the attenuated betacoronavirus strain of the present invention can further contain at least one of the following mutations (a), (c), (d), (g), (i) to (m), (p), and (q) as other mutations. (a) a mutation in NSP3 of the amino acid residue corresponding to valine at position 404 of the amino acid sequence set forth in SEQ ID NO:1; (c) a mutation in NSP3 at an amino acid residue corresponding to lysine at position 1792 of the amino acid sequence set forth in SEQ ID NO:1; (d) a mutation in NSP3 at an amino acid residue corresponding to aspartic acid at position 1832 of the amino acid sequence set forth in SEQ ID NO:1; (g) a mutation in NSP14 of an amino acid residue corresponding to alanine at position 504 of the amino acid sequence shown in SEQ ID NO:2; (i) a mutation in the spike of an amino acid residue corresponding to leucine at position 54 of the amino acid sequence shown in SEQ ID NO:4; (j) a mutation in the spike of an amino acid residue corresponding to threonine at position 739 of the amino acid sequence shown in SEQ ID NO:4; (k) a mutation in the spike of an amino acid residue corresponding to alanine at position 879 of the amino acid sequence shown in SEQ ID NO:4; (l) a mutation in the envelope of an amino acid residue corresponding to leucine at position 28 of the amino acid sequence shown in SEQ ID NO:5; (m) a mutation in the nucleocapsid of an amino acid residue corresponding to serine at position 2 of the amino acid sequence shown in SEQ ID NO:6; (p) a mutation in spike including a deletion of amino acid residues corresponding to positions 679 to 680 and positions 685 to 686 of the amino acid sequence shown in SEQ ID NO: 4; (q) A mutation in the amino acid residue in spike corresponding to valine at position 687 of the amino acid sequence shown in SEQ ID NO:4.

[0024] When the attenuated betacoronavirus strain of the present invention has other mutations, it is preferable to have the mutation (g) among the above-mentioned other mutations from the viewpoint of enhancing temperature sensitivity. When the attenuated betacoronavirus strain of the present invention has the mutation (g) as another mutation, it is preferable to use the mutation (g) together with a combination of the mutations (e) and (f) from the viewpoint of enhancing temperature sensitivity.

[0025] SEQ ID NO:1 is the amino acid sequence of NSP3 in SARS-CoV-2 at NC_045512 (NCBI); SEQ ID NO:2 is the amino acid sequence of NSP14 in SARS-CoV-2 at NC_045512 (NCBI); SEQ ID NO:3 is the amino acid sequence of NSP16 in SARS-CoV-2 at NC_045512 (NCBI).

[0026] Also, SEQ ID NO: 4 is the amino acid sequence of the spike in SARS-CoV-2 in NC_045512 (NCBI); SEQ ID NO: 5 is the amino acid sequence of the envelope in SARS-CoV-2 in NC_045512 (NCBI); and SEQ ID NO: 6 is the amino acid sequence of the nucleocapsid in SARS-CoV-2 in NC_045512 (NCBI).

[0027] Furthermore, SEQ ID NO:7 is the nucleotide sequence spanning a portion of the open reading frame of SARS-CoV-2 in NC_045512 (NCBI), specifically, a portion of ORF7a, the entire ORF7b, and most of ORF8; SEQ ID NO:8 is the amino acid sequence of NSP1 in SARS-CoV-2 in NC_045512 (NCBI).

[0028] The term "corresponding amino acid residue" refers to an amino acid residue present at the above-mentioned predetermined position in the amino acid sequence encoded by the amino acid sequence of SEQ ID NO: 1 to 4 (or 1 to 6), 8 or the nucleotide sequence shown in SEQ ID NO: 7 when the attenuated beta coronavirus strain of the present invention is a mutant strain of SARS-CoV-2 of NC_045512 (NCBI), and refers to an amino acid residue present at a position corresponding to the above-mentioned predetermined position in the amino acid sequence encoded by the amino acid sequence of SEQ ID NO: 1 to 4 (or 1 to 6), 8 or the nucleotide sequence shown in SEQ ID NO: 7 of a polypeptide possessed by another beta coronavirus when the attenuated beta coronavirus strain of the present invention is a mutant strain of SARS-CoV-2 other than the above-mentioned mutant strain. The corresponding position can be identified by aligning the amino acid sequences of a protein having the amino acid sequence of SEQ ID NO: 1 to 4 (or 1 to 6), 8 of SARS-CoV-2 of NC_045512 (NCBI) or a protein having an amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO: 7 with a protein of another beta coronavirus corresponding to the protein.

[0029] The attenuated virus strain of the present invention is not limited to the specific SARS-CoV-2 mutant strains listed in NC_045512 (NCBI) as long as the amino acid residue or amino acid sequence corresponding to the above-mentioned specified positions in the amino acid sequence of SEQ ID NO: 1 to 4 (or 1 to 6), 8, or the amino acid sequence encoded by the base sequence shown in SEQ ID NO: 7 is mutated, and therefore includes other betacoronavirus mutant strains [i.e., any other SARS-CoV-2 mutant strain, and mutant strains of viruses other than SARS-CoV-2 included in the betacoronavirus genus]. A specific SARS-CoV-2 mutant strain listed in NC_045512 (NCBI) refers to a mutant strain in which at least one of the amino acid residues or amino acid sequences at the above-mentioned specific positions in the amino acid sequence encoded by the amino acid sequence of SEQ ID NO: 1 to 4 (or 1 to 6), 8, or the nucleotide sequence shown in SEQ ID NO: 7 in the specific SARS-CoV-2 is mutated, and another betacoronavirus mutant strain refers to both any other SARS-CoV-2 mutant strain [i.e., a mutant strain in which the amino acid residue or amino acid sequence corresponding to the above-mentioned specific positions in the amino acid sequence encoded by the amino acid sequence of SEQ ID NO: 1 to 4 (or 1 to 6), 8, or the nucleotide sequence shown in SEQ ID NO: 7 in any other SARS-CoV-2] and a mutant strain of a virus other than SARS-CoV-2 included in the betacoronavirus genus [i.e., a mutant strain in which the amino acid residue or amino acid sequence corresponding to the above-mentioned specific positions in the amino acid sequence encoded by the amino acid sequence of SEQ ID NO: 1 to 4 (or 1 to 6), 8, or the nucleotide sequence shown in SEQ ID NO: 7 in a virus other than SARS-CoV-2 included in the betacoronavirus genus is mutated]. Any other SARS-CoV-2 mutant strain and mutant strains of viruses other than SARS-CoV-2 within the Betacoronavirus genus also include recombinant virus mutant strains in which the spike protein of SARS-CoV-2 or a betacoronavirus other than SARS-CoV-2 has been replaced with the spike protein of at least one other SARS-CoV-2 or betacoronavirus other than SARS-CoV-2 (including viruses that may be newly detected in the future).

[0030] Sequences corresponding to the amino acid sequences of SEQ ID NOs: 1 to 4 (or 1 to 6), 8, or the nucleotide sequence shown in SEQ ID NO: 7 in other beta coronavirus mutants are permitted to differ from the amino acid sequences of SEQ ID NOs: 1 to 4 (or 1 to 6), 8, or the nucleotide sequence shown in SEQ ID NO: 7, respectively, as long as the differences do not significantly affect the properties of the polypeptide. "Does not significantly affect the properties of the polypeptide" refers to a state in which the functions of each of the nonstructural proteins, structural proteins, and accessory proteins are maintained. Specifically, in the amino acid sequences of SEQ ID NOs: 1 to 4, 8, or the nucleotide sequence shown in SEQ ID NO: 7, differences from SEQ ID NOs: 1 to 4, 7, 8 (or 1 to 8) are permitted at sites other than the amino acid or nucleotide sequence corresponding to the above-mentioned specific mutations related to attenuation, or in sites other than the amino acid residues corresponding to other mutations in SEQ ID NOs: 5 and 6, if the amino acid sequences of SEQ ID NOs: 1 to 4, 8, or the nucleotide sequence shown in SEQ ID NO: 7 further have other mutations (sites other than the amino acid residues or nucleotides corresponding to these mutations are hereinafter also referred to as "arbitrary difference sites"). The acceptable difference may be one type of difference (e.g., substitution) selected from substitution, addition, insertion, and deletion, or may include two or more types of differences (e.g., substitution and insertion). The sequence identity calculated by comparing only any difference site between the amino acid sequence corresponding to SEQ ID NO: 1 to 4 (or 1 to 6), 8 or the nucleotide sequence shown in SEQ ID NO: 7 in any other SARS-CoV-2 and the amino acid sequence shown in SEQ ID NO: 1 to 4 (or 1 to 6), 8 or the nucleotide sequence shown in SEQ ID NO: 7 may be 50% or more. In any other SARS-CoV-2, the sequence identity is preferably 60% or more or 70% or more, more preferably 80% or more, even more preferably 85% or more or 90% or more, even more preferably 95% or more, 96% or more, 97% or more, or 98% or more, even more preferably 99% or more, particularly preferably 99.3% or more, 99.5% or more, 99.7% or more, or 99.9% or more. In any remaining betacoronavirus, the sequence identity is preferably 60% or greater.Here, "sequence identity" refers to the value of amino acid sequence identity obtained by the bl2seq program (Tatiana A. Tatsusova, Thomas L. Madden, FEMS Microbiol. Lett., Vol. 174, p. 247-250, 1999) of BLASTPACKAGE [sgi32 bit edition, Version 2.0.12; available from National Center for Biotechnology Information (NCBI)]. The parameters may be set as follows: Gap insertion Cost value: 11, Gap extension Cost value: 1.

[0031] That is, more specifically, the attenuated betacoronavirus strain of the present invention is as follows: An attenuated betacoronavirus strain comprising nonstructural proteins, accessory proteins and structural proteins each consisting of at least one of the following polypeptides (I), (II) and (III): (I) At least one of the following polypeptides (I-1) to (I-3) and the following ( I At least one of the polypeptides of (I-4) to (I-6): (I-1) A polypeptide (NSP3) consisting of an amino acid sequence having a substitution mutation (b') of leucine at position 445 as a temperature-sensitive mutation in the amino acid sequence shown in SEQ ID NO:1; (I-2) A polypeptide (NSP14) consisting of an amino acid sequence having a substitution mutation (e') of glycine at position 248 and a substitution mutation (f') of glycine at position 416 as temperature-sensitive mutations in the amino acid sequence shown in SEQ ID NO:2; (I-3) A polypeptide (NSP16) consisting of an amino acid sequence having a substitution mutation (h') of valine at position 67 as a temperature-sensitive mutation in the amino acid sequence shown in SEQ ID NO:3; (I-4) A polypeptide (ORF) consisting of an amino acid sequence having a deletion mutation (n') in the amino acid sequence encoded by the base sequence shown in SEQ ID NO: 7 as another attenuating mutation; (I-5) A polypeptide (spike) consisting of an amino acid sequence having a deletion mutation (o') at positions 681 to 684 in the amino acid sequence shown in SEQ ID NO: 4 as another attenuating mutation; (I-6) a polypeptide (NSP1) consisting of an amino acid sequence having a deletion mutation (r') at positions 32 to 39 in the amino acid sequence shown in SEQ ID NO:8 as a proliferation-reducing mutation; (II) a polypeptide constituting a betacoronavirus in which one or more amino acid residues other than the amino acid residues involved in the temperature-sensitive mutation and the amino acid sequence involved in the proliferation-reducing or other attenuating mutation in the amino acid sequence of the polypeptide of (I) have been substituted, added, inserted or deleted, thereby acquiring temperature sensitivity and attenuation ability; (III) A polypeptide constituting a betacoronavirus, which has a sequence identity of 50% or more for the amino acid sequence of the polypeptide (I) excluding the amino acid residues involved in the temperature-sensitive mutation and the amino acid sequences involved in the proliferation-reducing or other attenuating mutations, and which has acquired temperature sensitivity and attenuation ability.

[0032] When the more specific attenuated betacoronavirus strains described above contain other mutations in addition to temperature-sensitive mutations and growth-reducing and other attenuating mutations, as shown below, the above polypeptides (I-1) and (I-2) (nonstructural proteins) and the above polypeptide (I-5) (structural protein) may be the following polypeptides (I-1a), (I-2a), and (I-5a), respectively, which contain other mutations in addition to temperature-sensitive mutations and growth-reducing and other attenuating mutations, and the above polypeptide (I) may further include the following polypeptides (I-7a) and (I-8a) which contain other mutations. An attenuated betacoronavirus strain comprising structural proteins, accessory proteins and nonstructural proteins, the structural proteins comprising at least one of the following polypeptides (I), (II) and (III): (I) At least one of the following polypeptides (I-1a), (I-2a), and (I-3) and at least one of the following polypeptides (I-4), (I-5a), and (I-6), or in addition thereto, at least one of the following polypeptides (I-7a) and (I-8a): (I-1a) A polypeptide (NSP3) consisting of the amino acid sequence shown in SEQ ID NO:1, which has a temperature-sensitive mutation (b') of leucine at position 445 and, as other mutations, at least one of a mutation (a') of valine at position 404, a mutation (c') of lysine at position 1792, and a mutation (d') of aspartic acid at position 1832; (I-2a) A polypeptide (NSP14) consisting of the amino acid sequence shown in SEQ ID NO:2, which has temperature-sensitive mutations (e') at glycine at position 248 and (f') at glycine at position 416, and another mutation (g') at alanine at position 504. (I-3) A polypeptide (NSP16) consisting of the amino acid sequence shown in SEQ ID NO:3, which has a temperature-sensitive mutation (h') at position 67 of valine; (I-4) A polypeptide (ORF) consisting of an amino acid sequence having a deletion mutation (n') of the amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO: 7 as another attenuating mutation; (I-5a) A polypeptide (spike) consisting of an amino acid sequence having, in the amino acid sequence shown in SEQ ID NO: 4, a deletion mutation (o') at positions 681 to 684 as another attenuating mutation; and, as other mutations, at least one of a mutation of leucine at position 54 (i'), a mutation of threonine at position 739 (j'), and a mutation of alanine at position 879 (k'), and at least one of a deletion mutation (p') at positions 679 to 680 and 685 to 686 in the amino acid sequence, and a mutation (q') of valine at position 687; (I-6) A polypeptide (NSP1) consisting of an amino acid sequence having a deletion mutation (r') at positions 32 to 39 as a proliferation-reducing mutation in the amino acid sequence shown in SEQ ID NO:8. (I-7a) A polypeptide (envelope) consisting of the amino acid sequence shown in SEQ ID NO:5, which has a mutation (l') of leucine at position 28 as another mutation; (I-8a) A polypeptide (nucleocapsid) consisting of the amino acid sequence shown in SEQ ID NO:6, which has as another mutation a mutation (m') of serine at position 2; (II) A polypeptide constituting a betacoronavirus having temperature sensitivity and attenuation ability, in which the amino acid sequence of the polypeptide (I) is obtained by substituting, adding, inserting or deleting the amino acid sequence related to the temperature-sensitive mutation, the growth-reducing or other attenuating mutation, and one or more amino acid residues other than the amino acid sequence related to other mutations; (III) A polypeptide constituting a betacoronavirus which has acquired temperature sensitivity and attenuation ability, and which has an amino acid sequence identity of 50% or more for the amino acid sequence of the polypeptide (I) excluding the temperature-sensitive mutation, the amino acid sequence relating to the growth-reducing or other attenuating mutation, and the amino acid residues or amino acid sequences relating to other mutations.

[0033] The above mutations (a') to (r') refer to the mutations when the mutations (a) to (r) are specifically present in the amino acid sequences of SEQ ID NOs: 1 to 6, the nucleotide sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8, respectively. That is, the above polypeptide (I) is a polypeptide having the amino acid sequences of SEQ ID NOs: 1 to 6, the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8 of SARS-CoV-2 of NC_045512 (NCBI), into which a temperature-sensitive mutation and a growth-reducing or other attenuating mutation, or other mutations in addition to them, have been introduced. The above polypeptides (II) and (III) are polypeptides having the amino acid sequences of SEQ ID NOs: 1 to 6, the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 7, and the amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 8 of other beta coronaviruses, into which a temperature-sensitive mutation and a growth-reducing or other attenuating mutation, or other mutations in addition to them have been introduced. The preferred range of sequence identity of the above polypeptides (II) and (III) is as described above.

[0034] Betacoronavirus acquires temperature sensitivity by having the above-mentioned temperature-sensitive mutation, and can acquire excellent attenuation by having the above-mentioned growth-reducing and other attenuating mutations in addition to the above-mentioned temperature-sensitive mutation. The attenuated virus strain of the present invention has a growth ability at least lower than its growth ability at temperatures lower than the human lower respiratory tract temperature, and preferably has no growth ability at the human lower respiratory tract temperature. In the present invention, the temperature sensitivity is determined by comparing the virus titer (TCID50 / mL) in the culture supernatant after infecting Vero cells with the attenuated virus strain at MOI=0.01 at human lower respiratory tract temperature and culturing for one day at human lower respiratory tract temperature with the virus titer in the culture supernatant after infecting Vero cells with the attenuated virus strain at MOI=0.01 at human upper respiratory tract temperature and culturing for one day at human upper respiratory tract temperature, for example, 10 2 More than 10, preferably 3 This can be confirmed by the fact that the value has decreased by more than 100%.

[0035] Typically, the attenuated virus strain of the present invention has a reduced proliferation ability at human lower respiratory tract temperature compared to the proliferation ability at human lower respiratory tract temperature of a strain not having the above-mentioned temperature-sensitive mutation. This indicates that the virus titer (TCID50 / mL) in the culture supernatant after infecting Vero cells with the attenuated virus strain at MOI=0.01 at human lower respiratory tract temperature and culturing for one day at human lower respiratory tract temperature is, for example, 10% or more than the virus titer in the culture supernatant after infecting Vero cells with a strain not having the above-mentioned temperature-sensitive mutation at MOI=0.01 at human lower respiratory tract temperature and culturing for one day at human lower respiratory tract temperature. 2 More than 10, preferably 3 This can be confirmed by the fact that the value has decreased by more than 100%.

[0036] A typical example of the lower respiratory tract temperature in humans is about 37° C., and specifically, a temperature higher than the upper respiratory tract temperature described below, preferably 36 to 38° C., more preferably 36.5 to 37.5° C. or 37 to 38° C. In addition, the attenuated virus strain of the present invention may have the ability to grow at a temperature lower than the lower respiratory tract temperature in humans. For example, a temperature lower than the lower respiratory tract temperature in humans may include, for example, the upper respiratory tract temperature in humans (specifically, about 32 to 35.5° C.).

[0037] The above temperature-sensitive mutations are not present in the receptor-binding domain of the spike protein on the surface of the virus, which is important when the virus infects cells. Therefore, it is reasonably expected that the above temperature-sensitive mutations can be introduced to make the virus temperature sensitive, not only in the specific SARS-CoV-2 listed in NC_045512 (NCBI), but also in other betacoronaviruses. In other words, even if a mutation occurs that changes the immunogenicity of the virus due to a global infectious disease outbreak, it is reasonably expected that the above temperature-sensitive mutations can be further introduced into the mutant virus to confer temperature sensitivity to the mutant virus.

[0038] Regarding temperature-sensitive mutations, the mutation (b) above may be a substitution with an amino acid residue other than leucine, the mutation (e) above may be a substitution with an amino acid residue other than glycine, the mutation (f) above may be a substitution with an amino acid residue other than glycine, and the mutation (h) above may be a substitution with an amino acid residue other than valine. Regarding other mutations, the above mutation (a) may be a substitution with an amino acid residue other than valine, the above mutation (c) may be a substitution with an amino acid residue other than lysine, the above mutation (d) may be a substitution with an amino acid residue other than aspartic acid, the above mutation (g) may be a substitution with an amino acid residue other than alanine, the above mutation (i) may be a substitution with an amino acid residue other than leucine, the above mutation (j) may be a substitution with an amino acid residue other than threonine, the above mutation (k) may be a substitution with an amino acid residue other than alanine, the above mutation (l) may be a substitution with an amino acid residue other than leucine, the above mutation (m) may be a substitution with an amino acid residue other than serine, and the above mutation (q) may be a substitution with an amino acid residue other than valine.

[0039] In a preferred embodiment of the attenuated virus strain of the present invention, the temperature-sensitive mutations are: the mutation (b) is a substitution with phenylalanine, the mutation (e) is a substitution with valine and the mutation (f) is a substitution with serine, and / or the mutation (h) is a substitution with isoleucine. In the case where the preferred embodiment further has other mutations, the other mutations are: the mutation (a) is a substitution with alanine, the mutation (c) is a substitution with arginine, the mutation (d) is a substitution with asparagine, the mutation (g) is a substitution with valine, the mutation (i) is a substitution with tryptophan, the mutation (j) is a substitution with lysine, the mutation (k) is a substitution with valine, the mutation (l) is a substitution with proline, the mutation (m) is a substitution with phenylalanine, and / or the mutation (q) is a substitution with isoleucine.

[0040] In another example of the attenuated virus strain of the present invention, the substitution may be a so-called conservative substitution. Conservative substitution refers to substitution with an amino acid having a similar structure and / or properties. For example, examples of conservative substitution include substitution of a nonpolar amino acid with another nonpolar amino acid, substitution of an uncharged amino acid with another uncharged amino acid, substitution of an acidic amino acid with another acidic amino acid, and substitution of a basic amino acid with another basic amino acid. In general, "nonpolar amino acids" include alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine, and tryptophan, "uncharged amino acids" include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine, "acidic amino acids" include aspartic acid and glutamic acid, and "basic amino acids" include lysine, arginine, and histidine.

[0041] More preferred examples of the attenuated virus strain of the present invention include mutant strains of SARS-CoV-2 listed in NC_045512 (NCBI), in which the mutation (b) (i.e., the mutation (b')) is a substitution of leucine at position 445 of the amino acid sequence shown in SEQ ID NO: 1 in NSP3 with phenylalanine (L445F); the mutation (e) (i.e., the mutation (e')) is a substitution of glycine at position 248 of the amino acid sequence shown in SEQ ID NO: 2 in NSP14 with valine (G248V), and the mutation (f) (i.e., the mutation (f')) is a substitution of glycine at position 416 of the amino acid sequence shown in SEQ ID NO: 2 in NSP14 with serine (G416S); and / or the mutation (h) (i.e., the mutation (h')) is a substitution of valine at position 67 of the amino acid sequence shown in SEQ ID NO: 3 in NSP16 with isoleucine (V67I).Further, examples of the more preferred embodiment having other mutations include the mutation (a) (i.e., the mutation (a')) being a substitution of valine at position 404 in the amino acid sequence shown in SEQ ID NO:1 with alanine (V404A); the mutation (c) (i.e., the mutation (c')) being a substitution of lysine at position 1792 in the amino acid sequence shown in SEQ ID NO:1 with arginine (K1792R) in NSP3; and the mutation (d) (i.e., the mutation (d')). is a substitution of aspartic acid at position 1832 in the amino acid sequence shown in SEQ ID NO:1 with asparagine (D1832N) in NSP3; the mutation (g) (i.e., the mutation (g')) is a substitution of alanine at position 504 in the amino acid sequence shown in SEQ ID NO:2 with valine (A504V) in NSP14; and the mutation (i) (i')) is a substitution of leucine at position 54 in the amino acid sequence shown in SEQ ID NO:4 with tryptophan in spike. the (j) mutation (i.e., the (j') mutation) is a substitution of threonine at position 739 of the amino acid sequence shown in SEQ ID NO: 4 in the spike with lysine (T739K); the (k) mutation (i.e., the (k') mutation) is a substitution of alanine at position 879 of the amino acid sequence shown in SEQ ID NO: 4 in the spike with valine (A879V); the (l) mutation (i.e., the (l') mutation) is a substitution of alanine at position 879 of the amino acid sequence shown in SEQ ID NO: 5 in the envelope with valine (A879V). the (m) mutation (i.e., the (m') mutation) is a substitution of the serine at position 2 of the amino acid sequence shown in SEQ ID NO: 6 in the nucleocapsid with a phenylalanine (S2F); and / or the (q) mutation (i.e., the (q') mutation) is a substitution of the valine at position 687 of the amino acid sequence shown in SEQ ID NO: 4 in the spike with an isoleucine (V687I).

[0042] Particularly preferred examples of attenuated viral strains of the present invention include the following strains: a strain having, as temperature-sensitive mutations, the mutation (e) (preferably the mutation (e') and / or G248V), the mutation (f) (preferably the mutation (f') and / or G416S), and the mutation (h) (preferably the mutation (h') and / or V67I); and, as growth-reducing or other attenuating mutations, the mutation (n) (preferably the mutation (n')), the mutation (о), and the mutation (r); or a strain having, as further other mutations, the mutation (g) (preferably the mutation (g') and / or A504V), the mutation (p), and the mutation (q) (preferably the mutation (q') and / or V687I). a strain having, as temperature-sensitive mutations, the mutation (e) (preferably the mutation (e') and / or the G248V) and the mutation (f) (preferably the mutation (f') and / or the G416S); and, as growth-reducing or other attenuating mutations, the mutation (n) (preferably the mutation (n')), the mutation (о), and the mutation (r); or, as further other mutations, a strain having the mutation (g) (preferably the mutation (g') and / or the A504V), the mutation (p), and the mutation (q) (preferably the mutation (q') and / or the V687I). a strain having, as temperature-sensitive mutations, the mutation (e) (preferably the mutation (e') and / or G248V), the mutation (f) (preferably the mutation (f') and / or G416S), and the mutation (h) (preferably the mutation (h') and / or V67I); and, as other attenuating mutations, the mutation (n) (preferably the mutation (n')) and the mutation (о); or a strain having, as further other mutations, the mutation (g) (preferably the mutation (g') and / or A504V), the mutation (p), and the mutation (q) (preferably the mutation (q') and / or V687I). a strain having, as temperature-sensitive mutations, the mutation (b) (preferably the mutation (b') and / or L445F), the mutation (e) (preferably the mutation (e') and / or G248V), and the mutation (f) (preferably the mutation (f') and / or G416S); and, as other attenuating mutations, the mutation (n) (preferably the mutation (n')) and the mutation (о); or a strain having, as further other mutations, the mutation (c) (preferably the mutation (c') and / or K1792R), the mutation (g) (preferably the mutation (g') and / or A504V), the mutation (p), and the mutation (q) (preferably the mutation (q') and / or V687I). a strain having, as temperature-sensitive mutations, the mutation (b) (preferably the mutation (b') and / or L445F) and the mutation (h) (preferably the mutation (h') and / or V67I); and, as other attenuating mutations, the mutation (n) (preferably the mutation (n')) and the mutation (о); or a strain having, as further other mutations, the mutation (c) (preferably the mutation (c') and / or K1792R), the mutation (p), and the mutation (q) (preferably the mutation (q') and / or V687I). a strain having, as temperature-sensitive mutations, the mutation (e) (preferably the mutation (e') and / or G248V), the mutation (f) (preferably the mutation (f') and / or G416S), and the mutation (h) (preferably the mutation (h') and / or V67I); and, as growth-reducing or other attenuating mutations, the mutation (n) (preferably the mutation (n')) and the mutation (r) (preferably the mutation (r')); or a strain having, as another mutation, the mutation (g) (preferably the mutation (g') and / or A504V).

[0043] Most preferred examples of the attenuated viral strains of the present invention include the following strains: A strain having, as temperature-sensitive mutations, the mutation (e) (preferably the mutation (e') and / or G248V) and the mutation (f) (preferably the mutation (f') and / or G416S); and, as growth-reducing and other attenuating mutations, the mutation (n) (preferably the mutation (n')), the mutation (о), and the mutation (r); and, as further other mutations, a strain having the mutation (g) (preferably the mutation (g') and / or A504V), the mutation (p), and the mutation (q) (preferably the mutation (q') and / or V687I).

[0044] 2. Vaccines 2-1. Active ingredients of attenuated vaccines As described above, the attenuated betacoronavirus strain described in "1. Attenuated betacoronavirus strain" can only grow efficiently at temperatures lower than the lower respiratory tract temperature in humans due to the temperature-sensitive mutation, and therefore cannot grow efficiently at least deep inside the body, particularly in the lower respiratory tract including the lungs where serious damage occurs, and it is expected that the pathogenicity is significantly reduced. In addition, the attenuated betacoronavirus strain has limited growth regardless of temperature due to the growth-reducing and other attenuating mutations, and has excellent attenuation due to the combination with the above-mentioned temperature-sensitive mutation. By taking such a combined form, the attenuated betacoronavirus strain has the property that the deletion mutation, which is a growth-reducing and other attenuating mutation, is unlikely to revert, so that it is expected that the attenuated toxicity can be maintained even if the temperature-sensitive mutation is lost when the attenuated live vaccine is involved in growth in the host body.

[0045] Therefore, the attenuated virus strain itself can be used as a live attenuated vaccine by infecting a living body as an attenuated virus. Therefore, the present invention also provides a vaccine containing the above-mentioned attenuated betacoronavirus strain as an active ingredient. Details of the active ingredient are as described in "1. Attenuated betacoronavirus strain."

[0046] 2-2. Active ingredients of gene vaccines As described above in "1. Attenuated betacoronavirus strains," the specific mutation contributes to conferring attenuated toxicity. Therefore, the present invention also provides a betacoronavirus genetic vaccine that contains, as active ingredients, genes encoding nonstructural proteins, accessory proteins, and structural proteins having the above-mentioned specific mutations. Details of the specific mutations contained in the active ingredients are as described above in "1. Attenuated betacoronavirus strains."

[0047] 2-3. Targeted viruses The vaccine of the present invention can be reasonably expected to be effective against not only the initial Wuhan strain of the SARS-CoV-2 virus, but also a wide range of SARS-CoV-2 virus-related strains and viruses other than SARS-CoV-2 in the Betacoronavirus genus, including the variants detected in the UK in September 2020 and in South Africa in October 2020, as well as other known variants, and other unknown variants yet to be detected. Thus, the vaccine of the present invention targets Betacoronaviruses.

[0048] 2-4.Other ingredients In addition to the above-mentioned active ingredients, the vaccine of the present invention may contain other ingredients such as adjuvants, buffers, isotonicity agents, soothing agents, preservatives, antioxidants, odorants, light-absorbing pigments, stabilizers, carbohydrates, casein digests, and various vitamins, depending on the purpose and use.

[0049] Examples of adjuvants include animal oils (such as squalene) or their hydrogenated oils; vegetable oils (such as palm oil and castor oil) or their hydrogenated oils; oil-based adjuvants including anhydrous mannitol-oleate, liquid paraffin, polybutene, caprylic acid, oleic acid, and higher fatty acid esters; water-soluble adjuvants such as PCPP, saponin, manganese gluconate, calcium gluconate, manganese glycerophosphate, soluble aluminum acetate, aluminum salicylate, acrylic acid copolymer, methacrylic acid copolymer, maleic anhydride copolymer, alkenyl derivative polymer, oil-in-water emulsion, and cationic lipids containing quaternary ammonium salts; precipitating adjuvants such as aluminum salts, such as aluminum hydroxide (alum), aluminum phosphate, and aluminum sulfate, or combinations thereof, and sodium hydroxide; toxin components derived from microorganisms, such as cholera toxin and Escherichia coli heat-labile toxin; and other components (bentonite, muramyl dipeptide derivatives, interleukins, and the like).

[0050] Examples of the buffering agent include buffer solutions such as phosphate, acetate, carbonate, and citrate. Examples of the isotonicity agent include sodium chloride, glycerin, and D-mannitol. Examples of the soothing agent include benzyl alcohol. Examples of the preservative include thimerosal, paraoxybenzoic acid esters, phenoxyethanol, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, antibiotics, and synthetic antibacterial agents. Examples of the antioxidant include sulfite and ascorbic acid.

[0051] Examples of light absorbing dyes include riboflavin, adenine, adenosine, etc. Examples of stabilizers include chelating agents, reducing agents, etc. Examples of carbohydrates include sorbitol, lactose, mannitol, starch, sucrose, glucose, dextran, etc.

[0052] Furthermore, the vaccine of the present invention may contain one or more other vaccines against viruses or bacteria that cause diseases other than betacoronavirus infections, such as COVID-19, i.e., the vaccine of the present invention may be prepared as a combination vaccine containing other vaccines.

[0053] 2-5. Dosage form The dosage form of the vaccine of the present invention is not particularly limited and can be appropriately determined based on the administration method, storage conditions, etc. Specific examples of dosage forms include liquid preparations and solid preparations, and more specifically, oral administration agents such as tablets, capsules, powders, granules, pills, liquids, and syrups; dry preparations such as freeze-dried preparations, and parenteral administration agents such as injections, sprays, and patches (specifically, intramuscular administration agents, intradermal administration agents, subcutaneous administration agents, nasal administration agents, transdermal administration agents, etc.).

[0054] 2-6. Method of administration The method of administration of the vaccine of the present invention is not particularly limited and may be any of intramuscular, intraperitoneal, intradermal, subcutaneous, etc., injection, inhalation from the nasal cavity and oral cavity, and oral administration, etc.; preferred are intramuscular, intradermal, subcutaneous, etc., injection (intramuscular, intradermal, and subcutaneous administration), inhalation from the nasal cavity (intranasal administration), and absorption through the skin (transdermal administration), and more preferred is intranasal administration.

[0055] 2-7.Applicability The subjects to which the vaccine of the present invention can be applied are not particularly limited as long as they are subjects that may develop symptoms due to betacoronavirus infection (preferably subjects that may develop COVID-19 symptoms due to SARS-CoV-2 virus infection), and examples of such subjects include mammals, and more specifically, include humans; pet animals such as dogs and cats; and laboratory animals such as rats, mice, and hamsters.

[0056] 2-8.Dose The dose of the vaccine of the present invention is not particularly limited and can be appropriately determined depending on the type of active ingredient, the administration method, and the recipient (conditions such as age, weight, sex, and the presence or absence of underlying diseases).

[0057] The vaccine of the present invention is administered to humans at a dose of 1×10 PFU / body or more, preferably 1×10 2 PFU / body or more, preferably 2×10 2 PFU / body or more, more preferably 1×10 3 PFU / body or more, more preferably 2×10 3 The vaccine of the present invention can be administered to humans in a single dose of 6×10 PFU / body or more. 11 PFU / body or less, preferably 1×10 11 PFU / body or less, preferably 6×10 10 PFU / body or less, more preferably 1×10 10 Also includes PFU / body.

[0058] The dose of the vaccine of the present invention per human is 1×10 TCID50 / body or more, preferably 1×10 2 TCID50 / body or more, preferably 2×10 2 TCID50 / body or more, preferably 1×10 3 TCID50 / body or more, preferably 2×10 3 The vaccine of the present invention can be administered to humans in a single dose of 6×10 11 TCID50 / body or less, preferably 1×10 11 TCID50 / body or less, preferably 6×10 10 TCID50 / body or less, more preferably 1×10 10 TCID50 / body or less is also included.

[0059] 3. Method for producing attenuated strains of betacoronavirus The method for producing the attenuated betacoronavirus strain of the present invention is not particularly limited and can be appropriately determined by a person skilled in the art based on the above-mentioned amino acid sequence information. For example, from the viewpoint of producing a vaccine relatively inexpensively and with little lot-to-lot variation, a reverse genetics method using artificial chromosomes such as bacterial artificial chromosomes (BAC) or yeast artificial chromosomes (YAC), or a CPER method using a genome fragment of a betacoronavirus is preferably used.

[0060] In the method of reconstructing a virus using reverse genetics, first, the genome of a strain (parent strain) of an attenuated betacoronavirus strain that does not have any temperature-sensitive mutation, growth-reducing or other attenuating mutation is cloned. The parent strain used in this case may be any betacoronavirus, and specifically, may be selected from the group consisting of a specific SARS-CoV-2 listed in the above NC_045512 (NCBI), any other SARS-CoV-2 listed above, and viruses other than SARS-CoV-2 included in the betacoronavirus genus.

[0061] Furthermore, when using an artificial chromosome in the reverse genetics method, the full-length DNA of the viral genome is cloned into BAC DNA or YAC DNA, and a transcription promoter sequence for eukaryotic cells is inserted upstream of the viral sequence. Examples of the promoter sequence include the CMV promoter and the CAG promoter. A ribozyme sequence and a polyA sequence are inserted downstream of the viral sequence. Examples of the ribozyme sequence include the hepatitis D virus ribozyme and the hammerhead ribozyme. Examples of the polyA sequence include the polyA of the Simian 40 virus.

[0062] On the other hand, when using the CPER method in the reverse genetics method, the full-length DNA of the viral genome is divided into a plurality of fragments and cloned. Methods for obtaining the fragments include artificial synthesis of nucleic acids, PCR using the above artificial chromosome or the plasmid into which the fragments are cloned as a template, and the like.

[0063] To introduce at least any of the above-mentioned temperature-sensitive mutations, growth-reducing or other attenuating mutations, and other mutations as necessary into the viral genome cloned by the above-mentioned techniques, known point mutation introduction methods, such as homologous recombination methods such as double crossover and λ / RED recombination, overlap PCR, and CRISPR / Cas9 methods, can be used.

[0064] Subsequently, the artificial chromosome into which temperature-sensitive mutations, proliferation-reducing and other attenuating mutations, and other mutations as necessary are introduced is transfected into a host cell to reconstruct the recombinant virus. In the case of reverse genetics using the CPER method, fragments into which temperature-sensitive mutations, proliferation-reducing and other attenuating mutations, and other mutations as necessary are introduced are linked by a reaction using DNA polymerase, and then transfected into a host cell to reconstruct the recombinant virus. There is no particular limitation on the transfection method, and known methods can be used. There is also no particular limitation on the host, and known cells can be used.

[0065] The reconstructed recombinant virus is then added to cultured cells to subculture the recombinant virus. The cultured cells used are not particularly limited, and examples thereof include Vero cells, VeroE6 cells, Vero cells supplemented with TMPRESS2 expression, VeroE6 cells supplemented with TMPRESS2 expression, Calu-3 cells, 293T cells supplemented with ACE2 expression, BHK cells, 104C1 cells, mouse neuroblastoma-derived NA cells, and Vero cells. The virus can be collected by known methods such as centrifugation and membrane filtration. The collected virus can also be added to cultured cells to mass-produce the recombinant virus. EXAMPLES

[0066] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these.

[0067] [Test Example 1: Temperature-sensitive SARS-CoV-2 strain A50-18 (reference example)] [Test Example 1-1] Isolation of temperature-sensitive SARS-CoV-2 strain A50-18 Based on the method of FIG. 1, a SARS-CoV-2 clinical isolate (B-1 strain [comparative example]) (LC603286, also referred to in this embodiment as B-1 strain, wild strain (clinical isolate), European wild strain (B-1 strain), and B-1 strain (D614G type: pre-alpha European strain)) was added with two types of mutagenizers, 5-fluorouracil (hereinafter, 5-FU) and 5-azacytidine (hereinafter, 5-AZA), to obtain virus populations of the A-F50 series and the A-F500 series acclimatized at 32°C. Furthermore, each virus population was passaged multiple times, and from the 406 candidate strains obtained, a virus strain (A50-18 strain, hereinafter sometimes referred to as the Ts strain) that could grow at 32°C but had significantly reduced growth at 37°C was found, isolated, and selected (FIG. 2).

[0068] [Test Example 1-2] Analysis of temperature-sensitive strain A50-18 by next-generation sequencing (1-2-1) Mutation analysis of each virus strain Using a next-generation sequencer, we performed mutation analysis of the following virus strains. The analysis was performed by extracting RNA from the culture supernatant of Vero cells infected with SARS-CoV-2. The Wuhan clinical isolate Wuhan-Hu-1 (NC045512) was used as a reference. B-1: Wild strain (clinical isolate) A50-18: Temperature sensitive strain F50-37: non-temperature sensitive strain C500-1: non-temperature sensitive strain F500-53: non-temperature sensitive strain F500-40: non-temperature sensitive strain F500-2: non-temperature sensitive strain (All viruses except B-1 were mutated viruses)

[0069] (1-2-2) Mutations in temperature-sensitive strains The analysis results shown in Figure 3A were obtained from (1-2-1). The D614G point mutation is not characteristic of temperature-sensitive strains, since it is also found in the B-1 strain. On the other hand, characteristic point mutations of the temperature-sensitive strain (A50-18) were G248V, G416S, and A504V in NSP14, A879V in Spike, L28P in Envelope, and S2F in Nucleocapsid.

[0070] (1-2-3) Analysis of revertant strains 1 "Reversion" refers to the introduction of a further mutation in a mutated virus, resulting in the virus reverting to the same phenotype as the original virus before the mutation. As used herein, "reversion" refers to the introduction of a further mutation in a temperature-sensitive strain, resulting in the loss of temperature-sensitive properties. Further mutations include the reversion of the amino acid at the site of the mutation introduced when the virus was made temperature sensitive to the amino acid before the mutation.

[0071] Vero cells were infected with the B-1 strain or the A50-18 strain at MOI=0.01, and the growth ability at 32°C, 34°C, and 37°C was evaluated. As a result, a sample in which the growth ability at 37°C was restored was found among the A50-18 strain (hereinafter referred to as a "revertant strain"). In the revertant strain, it is considered that the temperature sensitivity was reduced and the growth ability at 37°C was restored by reverting some amino acid residues (hereinafter simply referred to as "revertant mutation") among the mutations of the temperature-sensitive strain (A50-18 strain) that had acquired temperature sensitivity to the amino acid before the mutation, which is reduced temperature sensitivity. The CPE image showing this is shown in Figure 3B. When the sequence of the obtained sample was confirmed, it was revealed that the mutation G248V in NSP14 was reverted to the wild type G, while the mutations G416S, A504V, and L28P in the envelope in NSP14 were maintained. This suggested that the G248V mutation in NSP14 was a responsible mutation (temperature-sensitive mutation) that contributes to temperature sensitivity.

[0072] (1-2-4) Analysis of reversion mutations in isolated strains 2 Vero cells were infected with the A50-18 strain at moi=1, and the proliferation ability at 37°C and 38°C was evaluated. As a result, samples (revertants) with restored proliferation ability at 37°C and 38°C were found. The CPE images of the obtained revertants after culturing them at 37°C for 3 days are shown in Figure 3C. The sequences of the obtained revertants were confirmed, and the following were found: <1> and <2> Two types of reversion patterns were found. <1> The G248V mutation in NSP14 reverted to wild-type G, while the G416S and A504V mutations remained. <2> The G416S mutation in NSP14 reverts to wild-type G, while the G248V and A504V mutations remain

[0073] Temperature sensitivity was lost when at least one of the G248V and G416S mutations in NSP14 was reversed, suggesting that the combination of the G248V and G416S mutations in NSP14 is the responsible mutation (temperature-sensitive mutation) that contributes to temperature sensitivity.

[0074] (1-2-5) Analysis of recombinant viruses with mutations introduced into wild-type NSP14, Spike, Nucleocapsid, and Envelope from the A50-18 strain were introduced by homologous recombination into BAC DNA containing the entire genome of wild-type SARS-CoV-2. The virus was reconstructed by transfecting the resulting recombinant BAC DNA into 293T cells. The recombinant virus was infected into Vero cells, and temperature sensitivity was evaluated by observing CPE at 37°C and 32°C. The results are shown in Figure 3D. By introducing NSP14 from the A50-18 strain, a temperature-sensitive strain that did not show CPE when cultured at 37°C was obtained, making it clear that NSP14 is the responsible mutation (temperature-sensitive mutation) that contributes to temperature sensitivity. On the other hand, since the introduction of the Envelope from the A50-18 strain did not result in temperature sensitivity, it is thought that the Envelope mutation does not contribute to temperature sensitivity.

[0075] (1-2-6) Analysis of recombinant viruses with mutations introduced into wild type 2 Using the CPER method, we reconstructed viruses with NSP14 mutations. Three types of recombinant viruses were reconstructed with the following NSP14 mutations: G248V only G416S only G248V and G416S (hereinafter, also referred to as "double mutant strains") Each recombinant virus was infected into Vero cells, and CPE was observed after 3 days of incubation at 37°C or 32°C. As shown in Figure 3-E, the virus with only the G248V mutation and the virus with only the G416S mutation showed CPE at 37°C and 32°C, similar to the B-1 strain, and thus it was found that they were not temperature-sensitive. On the other hand, the virus with the double mutant strain with the G248V and G416S mutations showed CPE at 32°C, but only a slight CPE was observed at 37°C, which was clearly weaker than that at 32°C. From the above results, it was revealed that the presence of the G248V and G416S mutations reduced the virus growth at 37°C and made it temperature-sensitive. From this, it was found that the combination of the G248V and G416S mutations in NSP14 is a responsible mutation (temperature-sensitive mutation) that contributes to temperature sensitivity.

[0076] (1-2-7) Analysis of temperature-sensitive strains by Sanger sequencing Mutation analysis of the A50-18 strain was performed using Sanger sequencing. The analysis was performed by extracting RNA from the culture supernatant of Vero cells infected with SARS-CoV-2. As a result, no deletions were found, as observed in (2-2-5) of Test Example 2-2 described below.

[0077] (1-2-8) Summary of mutations in temperature-sensitive strains In the temperature-sensitive strain A50-18, mutations marked with a check mark were found in the amino acid sequence of the indicated SEQ ID NO: as shown in Table 2 below, and among them, mutations marked with a double check mark were found to be temperature-sensitive mutations. In addition, as shown in Table 2 below, a double mutant strain having only a temperature-sensitive mutation in NSP14 was also found to be a temperature-sensitive strain.

[0078] [Table 2]

[0079] [Test Example 1-3] Growth analysis of temperature-sensitive strain A50-18 (1-3-1) Analysis at 32℃ and 37℃ A clinical isolate (B-1 strain [comparative example]) and a temperature-sensitive strain (A50-18 strain) were infected into Vero cells (N=3) using a 6-well plate at MOI=0.01 or 0.1. After culturing at 37°C or 32°C, the culture supernatants were collected 0 to 5 dpi. The viral titers of the culture supernatants 0 to 5 dpi were measured in TCID50 / mL using Vero cells. The results are shown in Figure 4A. As shown in Fig. 4A, the virus titer of the A50-18 strain 3 days after infection at 37°C was below the detection limit, indicating that the proliferation ability of the strain at 37°C was significantly reduced.

[0080] (1-3-2) Analysis at 32℃, 34℃, and 37℃ A clinical isolate (B-1 strain [comparative example]) and a temperature-sensitive strain (A50-18 strain) were infected into Vero cells (N=3) using a 6-well plate under the condition of MOI=0.01. After culturing at 37°C, 34°C, or 32°C, each culture supernatant was collected 0 to 5 dpi. The virus titer of the culture supernatant 0 to 5 dpi was measured in TCID50 / mL using Vero cells. The results are shown in Figure 4B. As shown in Fig. 4B, the A50-18 strain grew at 32°C and 34°C to the same extent as the clinical isolates, but showed a marked lack of growth ability at 37°C.

[0081] [Test Example 1-4] Pathogenicity analysis of temperature-sensitive strain A50-18 (1-4-1) Weight change in SARS-CoV-2 infected hamsters Four-week-old male Syrian hamsters (n=4) were raised for one week, and then the clinical isolate (B-1 strain [comparison example]) and the temperature-sensitive strain (A50-18 strain) (1x10 4 or 1x106 The mice were intranasally administered 100 μL of TCID50 of 100% nasal immunization medium, and the changes in body weight were observed for 10 days. The group that received the same amount of D-MEM medium intranasally was used as a non-infected control (MOCK). The results are shown in Figure 5. As shown in FIG. 5, no weight loss was observed upon infection with the A50-18 strain, suggesting that the pathogenicity of the strain is extremely low.

[0082] (1-4-2) Virus load in the lungs or nasal cavities of SARS-CoV-2-infected hamsters Four-week-old male Syrian hamsters (n=3) were raised for one week, and then the clinical isolate (B-1 strain [comparison example]) and the temperature-sensitive strain (A50-18 strain) (1x10 6 The virus was administered intranasally at a dose of 100 μL (TCID50). The results of observing the weight change over 3 days are shown in Figure 6. After euthanasia of the hamsters at 3 dpi, the nasal wash was collected with 1 mL of D-PBS. The lungs of the hamsters were also removed, the right lung was crushed, suspended in 1 mL of D-MEM, and the supernatant was collected as the lung crushed fluid by centrifugation. The amount of virus in these nasal washes and lung crushed fluids was evaluated by plaque formation assay using Vero cells, and the results are shown in Figure 7. Furthermore, the removed left lung was fixed in 10% formalin and photographed, which is shown in Figure 8.

[0083] Figure 7 shows that there was no difference in the amount of virus between the B-1 and A50-18 strains in the nasal washings, but the amount of virus in the A50-18 strain was significantly less in the lungs. Figure 8 also shows that hamsters infected with the B-1 strain and losing weight showed swelling and blackening of the lungs, while hamsters infected with the A50-18 strain showed no change in weight or significant changes in the lungs. From these results, it was presumed that the temperature-sensitive strain was an attenuated strain that could grow in the upper respiratory tract but could not grow in the lower respiratory tract.

[0084] (1-4-3) Histological analysis of SARS-CoV-2-infected hamsters Sections were prepared from the formalin-fixed lungs obtained in the infection experiment on hamsters conducted in (1-4-2) and stained with HE to analyze the histological pathogenicity of the lungs due to SARS-CoV-2 infection. The results are shown in Figure 9.

[0085] As shown in FIG. 9, infiltration of erythrocytes and collapse of alveolar structure were observed in the lungs obtained from hamsters infected with a clinically isolated strain (B-1 strain [comparative example]). On the other hand, such severe symptoms were not observed in the lungs of hamsters infected with a temperature-sensitive strain (A50-18 strain). This also strongly suggests that the A50-18 strain does not induce severe inflammation in the lungs upon infection and has low pathogenicity.

[0086] (1-4-4) Histological analysis of SARS-CoV-2-infected hamsters using immunochemical staining Regarding the histological pathogenicity observed in (1-4-3), in order to evaluate the relationship between viral proliferation and pathogenicity, viral proteins were detected by immunochemical staining. Four-week-old male Syrian hamsters (B-1, A50-18: n=5, MOCK: n=3) were kept for one week, and then the clinical isolate (B-1 strain [comparison example]) and the temperature-sensitive strain (A50-18 strain) (1x10 6The hamsters were euthanized at 3 dpi, and the left lungs were removed and fixed in 10% formalin, and serial sections were prepared. HE staining and immunochemical staining (also called immunohistochemistry (IHC) staining) were performed on the serial sections obtained. A rabbit anti-spike polyclonal antibody (Sinobiological: 40589-T62) was used for immunochemical staining. HE staining and immunochemical staining images are shown in Figure 10. As in (1-4-3), infiltration of red blood cells and collapse of alveolar structure were observed in the B-1 strain-infected hamsters, and spike protein was detected over a wide area by immunochemical staining. On the other hand, no such tissue damage was observed in the A50-18 strain-infected hamsters, and spike protein was detected only in a localized limited area. These results also demonstrated that the B-1 strain caused significant virus proliferation in lung tissue and tissue damage, whereas the A50-18 strain caused virus inefficient proliferation in lung tissue and low lung tissue damage.

[0087] [Test Example 1-5] Immunogenicity analysis of temperature-sensitive strain A50-18 (1-5-1) Wild-type challenge test on hamsters infected with temperature-sensitive strains A challenge test of the temperature-sensitive strain-infected hamsters with the wild-type strain (clinical isolate) was carried out according to the following procedure. Four-week-old male Syrian hamsters (n=4) were raised for one week and then inoculated with either a clinical isolate (B-1 strain [comparison example]) or a temperature-sensitive strain (A50-18 strain) (1x10 4 or 1x10 6 After 21 days, the clinical isolate (B-1 strain) (1x10 6 The hamsters were intranasally administered 100 μL of 100% TCID50 of the virus and their body weight changes were observed for 10 days. Uninfected hamsters of the same age (n=3) were used as naive controls. The results are shown in Figure 11.

[0088] As shown in Figure 11, naive hamsters were observed to lose weight upon infection with the B-1 strain, whereas hamsters infected once with the B-1 or A50-18 strains did not lose weight. This demonstrated that infection with not only the wild-type B-1 strain but also the less pathogenic A50-18 strain induces immunity that contributes to protection against infection.

[0089] (1-5-2) Analysis of neutralizing antibody induction in hamsters infected with temperature-sensitive strains Four-week-old male Syrian hamsters (n=5) were raised for one week and then inoculated with either a clinical isolate (B-1 strain [comparison example]) or a temperature-sensitive strain (A50-18 strain) (1x10 6 The TCID50 was administered intranasally at a dose of 100 μL. The changes in body weight after infection are shown in Figure 12. As in the previous results, infection with the B-1 strain caused a decrease in body weight, whereas infection with the A50-18 strain did not cause a decrease in body weight.

[0090] At 21 days after infection, whole blood was collected, serum was separated, and the serum was heat inactivated at 56°C for 30 minutes. 100 TCID50 of the B-1 strain was mixed with serially diluted inactivated serum and reacted at 37°C for 1 hour. The culture solution after the reaction was inoculated onto Vero cells, and after incubation at 37°C, the virus neutralizing activity was evaluated by observing CPE. The highest dilution rate that did not cause CPE was taken as the neutralizing antibody titer. The results are shown in Figure 13. While serum from uninfected hamsters did not show neutralizing activity against the B-1 strain, serum from hamsters infected with the B-1 strain or the A50-18 strain was able to induce neutralizing antibodies.

[0091] [Test Example 2: SARS-CoV-2 temperature-sensitive strains H50-11, L50-33, and L50-40 (Example)] [Test Example 2-1] Additional isolation of SARS-CoV-2 temperature-sensitive strains H50-11, L50-33, and L50-40 In order to isolate further candidate strains, temperature-sensitive strains were isolated using the method of FIG. 14. A clinical isolate of SARS-CoV-2 (B-1 strain [comparison example]) was infected into Vero cells, and virus populations of the G to L50 series were obtained by adding the mutagen 5-FU and adapting the cells at 32°C. Furthermore, each virus population was passaged multiple times, and from the 253 strains obtained, virus strains (H50-11 strain, L50-33 strain, L50-40 strain) that could grow at 32°C but had significantly reduced growth at 37°C were found, isolated, and selected (FIG. 15).

[0092] [Test Example 2-2] Analysis of temperature-sensitive additional isolated strains H50-11, L50-33, and L50-40 by next-generation sequencing (2-2-1) Mutation analysis method for additional isolated strains Using a next-generation sequencer, we performed mutation analysis of the following virus strains. The analysis was performed by extracting RNA from the culture supernatant of Vero cells infected with SARS-CoV-2. The Wuhan clinical isolate Wuhan-Hu-1 (NC045512) was used as a reference. H50-11 strain: temperature sensitive strain Strain L50-33: Temperature sensitive strain L50-40 strain: temperature sensitive strain

[0093] (2-2-2) Temperature-sensitive mutant analysis results The analysis results shown in FIG. 16A were obtained in (2-2-1). Characteristic point mutations of the H50-11 strain were V404A and D1832N in NSP3, V67I in NSP16, and T739K in Spike. Characteristic point mutations of the L50-33 strain were L445F and K1792R in NSP3, and characteristic point mutations of the L50-40 strain were L445F and K1792R in NSP3, and L54W in Spike.

[0094] (2-2-3) Analysis of revertants of additional isolated strains (H50-11 strain) The H50-11 strain was infected into Vero cells at moi=1, and the proliferation at 37°C and 38°C was evaluated. As a result, samples (revertants) with restored proliferation at 37°C and 38°C were found. The CPE images of the obtained revertants after culturing them at 38°C for 3 days are shown in FIG. 16B. When the sequences of the obtained samples were confirmed, the NSP16 V67I mutation had reverted to the wild-type V, while other amino acid mutations were maintained. This suggested that the NSP16 V67I mutation was a responsible mutation (temperature-sensitive mutation) that contributes to temperature sensitivity.

[0095] (2-2-4) Analysis of revertants of additional isolated strains (L50-33 and L50-40 strains) Vero cells were infected with the L50-33 and L50-40 strains at MOI=0.01, and their proliferation at 32°C, 34°C, and 37°C was evaluated. As a result, samples in which proliferation at 37°C was restored (hereinafter, revertants) were found among the L50-33 and L50-40 strains. The CPE images of each strain after culturing at 37°C for 3 days are shown in FIG. 16C. The revertants of the L50-33 and L50-40 strains are shown as L50-33 Rev1 and 2 and L50-40 Rev1 and 2, respectively. When the sequences of the obtained samples were confirmed, it was revealed that the L445F mutation in NSP3 had mutated to wild-type L or C, while the K1792R mutation in NSP3 was maintained. This suggested that the L445F mutation in NSP3 may be a responsible mutation (temperature-sensitive mutation) that contributes to temperature sensitivity.

[0096] (2-2-5) Analysis of temperature-sensitive strains by Sanger sequencing Mutation analysis of the H50-11, L50-33, and L50-40 strains was performed using Sanger sequencing, using RNA extracted from the culture supernatant of Vero cells infected with SARS-CoV-2.

[0097] As a result, deletion of the nucleotide sequence from positions 27549 to 28251 (SEQ ID NO: 7) was found in all three strains as shown in Figure 17. A schematic diagram of the deletion of the nucleotide sequence from positions 27549 to 28251 and the deletion of the amino acid sequence encoded thereby is shown in Figure 18. In addition, in Figure 18, ORF7a is the nucleotide sequence from positions 27394 to 27759, ORF7b is the nucleotide sequence from positions 27756 to 27887, and ORF8 is the nucleotide sequence from positions 27894 to 28259.

[0098] As shown in Figure 18, the nucleotide sequence region from positions 27549 to 28251 corresponds to a portion of ORF7a (amino acid sequence from position 53 to the end; the same applies below), the entire ORF7b, and most of the amino acid sequence of ORF8. Since the deletion of this region is accompanied by a frameshift, it is believed that a protein was produced in which the amino acid sequence from positions 1 to 52 of ORF7a was fused with the amino acid sequence encoded by the 3'-terminal 8 bases of ORF8 and the nucleotide sequence of the intergenic region and nucleocapsid. Furthermore, the entire ORF7b was deleted, and the original sequence of ORF8 was also deleted in its entirety.

[0099] (2-2-6) Summary of mutations in temperature-sensitive strains In the temperature-sensitive strains H50-11, L50-33, and L50-40, mutations marked with a check mark were found in the amino acid sequences of the indicated sequence numbers, as shown in Table 3 below, and among them, mutations marked with a double check mark were found to be temperature-sensitive mutations.

[0100] [Table 3]

[0101] [Test Example 3] Growth analysis of additional isolated strains H50-11, L50-33, and L50-40 (Example) Vero cells were infected with the additional isolates at an MOI of 0.01 (N=3). After culturing at 37°C, 34°C, or 32°C, the culture supernatants were collected 0 to 5 dpi. The virus titers of the culture supernatants were calculated as TCID 50The concentration of β-lactamase in the additional isolates was measured at 100 μg / mL using Vero cells, and the results are shown in Figure 19. The additional isolates showed growth potential at 32°C and 34°C, but showed reduced growth potential at 37°C.

[0102] [Test Example 4] Pathogenicity analysis of each temperature-sensitive strain (4-1) Body weight change in hamsters infected with temperature-sensitive strains Four-week-old male Syrian hamsters (n=5) were raised for one week, and then infected with a clinical isolate (B-1 strain [Comparative Example]) or a temperature-sensitive strain (A50-18 strain [Reference Example], and L50-33 strain, L50-40 strain, and H50-11 strain [Example]) (3x10 5 The hamsters were intranasally administered 100 μL of TCID50 of the virus, and body weight changes were observed for 10 days. The group that received the same amount of D-MEM medium intranasally was used as a non-infected control (MOCK). The results are shown in Figure 20. Hamsters infected with the B-1 strain showed a weight loss of about 20% over 7 days, whereas no significant weight loss was observed in any of the groups of hamsters infected with the temperature-sensitive strain, suggesting that the pathogenicity of the virus was significantly low.

[0103] (4-2) Virus load in the lungs or nasal cavities of hamsters infected with temperature-sensitive strains Four-week-old male Syrian hamsters (n=5) were raised for one week, and then infected with a clinical isolate (B-1 strain [Comparative Example]) or a temperature-sensitive strain (A50-18 strain [Reference Example], and L50-33 strain, L50-40 strain, and H50-11 strain [Example]) (3x10 5 The virus was administered intranasally at a dose of 100 μL (TCID50). After euthanasia of the hamsters at 3 dpi, the nasal wash was collected with 1 mL of D-PBS. The lungs of the hamsters were removed and their weights were measured. The right lung was crushed and suspended in 1 mL of D-MEM, and the supernatant was collected as the lung homogenate by centrifugation. The lung weight per total body weight of the hamsters is shown in Figure 21. The amount of virus in the nasal wash and the lung homogenate was evaluated by plaque formation assay using Vero cells, and the results are shown in Figure 22.

[0104] As a result of comparing the lung weight per total body weight of the hamsters, the lung weight of the hamsters infected with the B-1 strain was increased, strongly suggesting that the lungs were swollen due to inflammation. On the other hand, such an increase in lung weight was not observed in the hamsters infected with the temperature-sensitive strains. In addition, as a result of comparing the amount of virus in the nasal wash, there was no significant difference between the hamsters infected with the B-1 strain and those infected with the temperature-sensitive strains except for the H50-11 strain, and the amount of virus in the nasal wash was smaller in the hamsters infected with the H50-11 strain. Furthermore, it was revealed that the amount of virus in the lungs of the hamsters infected with the temperature-sensitive strains was significantly smaller than that of the B-1 strain. From these results, it was inferred that each temperature-sensitive strain was an attenuated strain that could not grow in the lower respiratory tract, similar to the A50-18 strain in Test Example 1.

[0105] [Test Example 5] Immunogenicity analysis of each temperature-sensitive strain (5-1) Wild-type challenge test on hamsters infected with temperature-sensitive strains Four-week-old male Syrian hamsters (n=5) were raised for one week, and then infected with a clinical isolate (B-1 strain [Comparative Example]) or a temperature-sensitive strain (A50-18 strain [Reference Example], and L50-33 strain, L50-40 strain, and H50-11 strain [Example]) (3x10 5 After 21 days, the clinical isolate (B-1 strain) (3x10 5 The hamsters were intranasally administered 100 μL of TCID50 of the virus and the body weight changes were observed for 9 days. Uninfected hamsters of the same age (n=5) were used as naive controls. The results are shown in Figure 23. While the naive hamsters were observed to lose weight upon infection with the B-1 strain, the hamsters infected once with the B-1 strain and each temperature-sensitive strain did not lose weight. This demonstrated that immunity contributing to protection against infection can be induced not only by the wild type B-1 strain but also by each temperature-sensitive strain with low pathogenicity.

[0106] (5-2) Analysis of neutralizing antibody induction in hamsters infected with temperature-sensitive strains Four-week-old male Syrian hamsters (n=5) were raised for one week, and then infected with a clinical isolate (B-1 strain [Comparative Example]) or a temperature-sensitive strain (A50-18 strain [Reference Example], and L50-33 strain, L50-40 strain, and H50-11 strain [Example]) (3x10 5 A dose of 100 μL of TCID50 was administered intranasally. After 20 days, partial blood samples were taken and the obtained serum was used to measure neutralizing activity against a clinically isolated strain (B-1 strain). The neutralizing activity was measured using the same method as in (1-5-2). The measurement results are shown in Figure 24. It was revealed that antibodies with neutralizing activity were induced not only in hamsters infected with the B-1 strain, but also in hamsters infected with each temperature-sensitive strain.

[0107] [Test Example 6] Analysis of efficacy against SARS-CoV-2 mutant strains (reference example) Evaluation of neutralizing activity of sera from hamsters infected with temperature-sensitive strains against SARS-CoV-2 mutant strains Four-week-old male Syrian hamsters (n=3 or 5) were raised for one week, and then incubated with either a clinical isolate (B-1 strain [Comparative Example]) or a temperature-sensitive strain (A50-18 strain [Reference Example]) (3x10 5 The vaccine was administered intranasally at a dose of 100 μL (TCID50). Partial blood samples were taken from the hamsters 3 weeks after infection, and the neutralizing activity against live SARS-CoV-2 European clinical isolate (B-1) and Brazilian variant (hCoV-19 / Japan / TY7-503 / 2021 strain) was measured using the obtained serum. The neutralizing activity was measured using the same method as in (1-5-2). It was revealed that hamsters infected with the B-1 strain and temperature-sensitive strain also exhibited neutralizing activity against the Brazilian variant. This suggests that this live attenuated vaccine is also effective against SARS-CoV-2 variants.

[0108] [Test Example 7] Comparative study of administration route and dosage (reference example) (7-1) Comparison of immune induction ability depending on administration route Four-week-old male Syrian hamsters (n=5) were raised for one week, and then inoculated with either a clinical isolate (B-1 strain [Comparative Example]) or a temperature-sensitive strain (A50-18 strain [Reference Example]) (3x10 5The hamsters were administered 100 μL of TCID50 intranasally or subcutaneously. The untreated group was used as the naive control. Three weeks later, serum obtained by partial blood collection from the hamsters was used to evaluate the neutralizing activity against the SARS-CoV-2 Brazilian variant (hCoV-19 / Japan / TY7-503 / 2021 strain). The same method as in (1-5-2) was used to measure the neutralizing activity. The results of the neutralizing activity are shown in Figure 26. "in" indicates intranasal administration, and "SC" indicates subcutaneous administration. Intranasal administration of the B-1 and A50-18 strains was able to induce neutralizing antibodies against the live virus. Subcutaneous administration was unable to induce almost any neutralizing antibodies at the doses tested, but considering the results of nasal administration, it was thought that subcutaneous administration could also induce neutralizing antibodies by increasing the dose.

[0109] (7-2) Comparison of immune induction ability by dose Four-week-old male Syrian hamsters (n=5) were raised for one week, and then the temperature-sensitive strain (A50-18 strain) was administered intranasally or subcutaneously. The doses are shown in Table 4.

[0110] [Table 4]

[0111] Partial blood samples were taken from hamsters 3 weeks after infection, and the serum obtained was used to measure the neutralizing activity against the live virus of the SARS-CoV-2 Brazilian variant (hCoV-19 / Japan / TY7-503 / 2021 strain). The results are shown in Figure 27. "in" indicates intranasal administration, and "SC" indicates subcutaneous administration. The method for measuring neutralizing activity was the same as in (1-5-2). As in (7-1), for intranasal administration, 1x10 2 An increase in neutralizing antibody titers was observed even in the low-dose group (TCID50 / 10 μL). This suggests that temperature-sensitive strains may be able to induce sufficient immunity even with small intranasal doses. Subcutaneous administration did not induce much neutralizing antibody at the doses tested, but considering the results of intranasal administration, it is believed that subcutaneous administration can induce neutralizing antibodies if the dose is increased.

[0112] [Test Example 8] Analysis of efficacy against SARS-CoV-2 mutant strains (reference example) Four-week-old male Syrian hamsters (n=4) were raised for one week and then injected with 1x10 4 TCID50 or 1x10 2 A 10 μL dose of TCID50 of a temperature-sensitive strain (A50-18 strain [reference example]) was administered intranasally. Partial blood was collected from hamsters 3 weeks after infection, and the neutralizing activity against live SARS-CoV-2 European wild type strain (B-1 strain), Indian variant strain (self-isolated strain), and Brazilian variant strain (hCoV-19 / Japan / TY7-503 / 2021 strain) was measured using the obtained serum. The results are shown in Figure 28. The method for measuring neutralizing activity was the same as in (1-5-2). It was revealed that not only the parent wild type B-1 strain, but also individuals administered a small amount of the A50-18 strain intranasally were able to induce neutralizing antibodies against the Indian variant and Brazilian variant in a dose-dependent manner.

[0113] In addition, the results of comparing the neutralizing antibody titers of each individual's serum against each strain are shown in Figure 29. Although a decrease in neutralizing antibody titers was observed in some individuals against the Brazilian variant, it was revealed that all individuals possessed neutralizing antibodies. These results suggest that immunization by intranasal administration of the temperature-sensitive strain may provide cross-protection.

[0114] [Test Example 9] Creation of vaccine candidate strains by CPER reaction (Example) Since live attenuated vaccines inherently grow in the host body, there is a possibility that highly virulent wild-type strains may develop due to mutations that occur during nucleic acid replication. To reduce this possibility, a strain was constructed that combines temperature-sensitive mutations with growth-reducing and other attenuating mutations. Such a strain was constructed so that attenuation can be maintained even if the temperature-sensitive mutation is lost. As temperature-sensitive mutations, growth-reducing and other attenuating mutations, and other mutations, the mutations shown in Table 5 with a check mark were used [i.e., L445F in NSP3, G248V and G416S in NSP14, and V67I in NSP16; deletion of 8 amino acids at positions 32 to 39 in NSP1, deletion of the furin cleavage site (FCS) in spike (specifically, deletion of positions 679 to 686 in spike and V687I), functional deletion of ORF8; or other mutations found in temperature-sensitive strains (NSP3 K1792R and NSP14 A504V)].

[0115] [Table 5]

[0116] Using reverse genetics with CPER, we constructed a strain that has the above-mentioned temperature-sensitive mutations in combination with growth-reducing and other attenuating mutations along with other mutations (Torii et al. Cell Report 2020). The genome of the SARS-CoV-2 B-1 strain was fragmented and cloned into a plasmid. The desired mutation was introduced into the cloned fragment using inverse PCR. Using the plasmid into which the wild-type fragment was cloned as a template, a SARS-CoV-2 wild-type genome fragment was obtained by PCR. In addition, using the plasmid into which the mutation was introduced or the genome of a SARS-CoV-2 mutant strain with the desired mutation as a template, a SARS-CoV-2 mutant genome fragment was obtained by PCR or RT-PCR.

[0117] The resulting fragments and a linker fragment containing a CMV promoter were mixed, and multiple fragments were circularized by CPER using PrimeStar GXL polymerase. The reaction solution was transfected into BHK / hACE2 cells and cultured at 34°C to reconstruct the target virus. The culture supernatant of the obtained cells was added to VeroE6 / TMPRSS II cells and cultured at 34°C to perform recovery culture of the reconstructed virus. The temperature-sensitive mutations and / or growth-reducing and other attenuating mutations introduced into each candidate strain and the CPE image are shown in Figure 30. Since CPE was observed in VeroE6 / TMPRSS II cells, it was clear that the virus was reconstructed.

[0118] [Test Example 10] Evaluation of temperature sensitivity of candidate strains (Example) (10-1) Temperature sensitivity of candidate strains 1 to 7 To evaluate the temperature sensitivity of candidate strains 1 to 7 (Example) obtained in Test Example 9, 2 μL of the supernatant of the recovery culture of each candidate strain was infected into Vero cells, and the proliferation at 34° C. and 37° C. was compared. The CPE image after 3 days of culture is shown in FIG. 31A. All strains showed CPE at 34° C., whereas candidate strains 1, 2, 3, 6, and 7 did not show CPE at 37° C. Candidate strains 4 and 5 showed slight CPE, but the degree was weaker than that at 34° C. This confirmed that the vaccine candidate strains showed temperature sensitivity.

[0119] (10-2) Temperature sensitivity of the strain reconstructed by introducing all temperature-sensitive mutations A strain (rTs-all strain [Example]) was obtained by introducing all temperature-sensitive mutations. The rTs-all strain had three types of temperature-sensitive mutations introduced: the mutation in (b), a combination of the mutations in (e) and (f), and the mutation in (h). As other attenuating mutations, only the mutation in (n) was introduced, and no other mutations were introduced.

[0120] Vero cells were infected with the rTs-all strain at MOI=0.01 and cultured at 32, 37, and 39°C for 5 days, and the culture supernatant was sampled over time (n=3). The virus titer at each time point was measured by the TCID50 method. For comparison, the B-1 strain (rB-1 strain) prepared by the CPER method was used. The obtained growth curve is shown in Figure 31B. As shown in Figure 31B, the rTs-all strain grew at 32°C, while its growth rate at 37°C and 39°C was significantly reduced (it fell below the detection limit on day 1 and did not grow thereafter). In addition, since the growth of the rTs-all strain at 32°C was slightly delayed compared to the rB-1 strain, it was recognized that the level of temperature sensitivity was expressed more strongly than the preferred level (i.e., its growth rate at 32°C was comparable to that of the rB-1 strain). These results indicate that in order to control the level of temperature sensitivity to a desired level, it is preferable to select one or two of the temperature-sensitive mutations (i.e., the three mutations or combinations of mutations (b), the combination of mutations (e) and (f), and the mutation (h)) rather than selecting three.

[0121] [Test Example 11] Immunogenicity evaluation of candidate strains 1, 3, 4, 6, and 7 at low titers and low doses (neutralizing antibody titer induction) (Example) To evaluate the immunogenicity of candidate strains 1, 3, 4, 6, and 7 (Examples) among the candidate strains obtained in Test Example 9, 100 TCID50 of each candidate strain was administered intranasally to five 5-week-old male hamsters at 10 μL. In addition, the SARS-CoV-2 temperature-sensitive strain A50-18 was administered intranasally at the same titer and dose as a positive control. After 3 weeks, partial blood collection was performed and the neutralizing activity of the serum obtained against the SARS-CoV-2 B-1 strain was evaluated. The neutralizing activity was evaluated by a method in which serially diluted serum was mixed with 100 TCID50 of SARS-CoV-2, reacted for 1 hour, added to Vero cells, and cultured for 4 days to observe CPE to determine the presence or absence of infectious virus. The maximum dilution ratio of the serum that did not show CPE and was able to neutralize the infectivity of the virus was defined as the neutralizing antibody titer. The results are shown in Figure 32.

[0122] In the hamsters infected with the A50-18 strain (reference example), which is the positive control group, the neutralizing activity was observed to be positive in all individuals. In the candidate strains 1 and 3, the neutralizing activity was not observed to be positive under the administration conditions in this test example, suggesting that a higher dose must be administered to express immunogenicity. On the other hand, in the candidate strains 4, 6, and 7, the neutralizing activity was observed to be positive in some or all individuals, indicating that they had immunogenicity even at a low dose such as in this test example. In particular, in the hamsters infected with the candidate strain 7 (example), the neutralizing activity was observed to be positive in all individuals, similar to the A50-18 strain, and the degree of immunogenicity was particularly excellent. In other words, among the candidate strains in which positive neutralizing activity was observed under the administration conditions in this test example, candidate strains 4 and 6 were constructed by combining temperature-sensitive mutations with other attenuating mutations, thereby improving safety. In particular, candidate strain 7 was constructed by combining a temperature-sensitive mutation with growth-reducing and other attenuating mutations, thereby maintaining excellent immunogenicity despite its significantly reduced growth ability in the body.

[0123] [Test Example 12] Immunogenicity evaluation of candidate strain 7 at low titer and low dose (challenge test) (Example) To evaluate whether the immunity induced by candidate strain 7 contributes to protection from infection, hamsters (male, 8 weeks old) were injected with 3 × 10 5 A challenge test was conducted by intranasally administering 100 μL of TCID50 of the SARS-CoV-2 B-1 strain. The weight changes of the hamsters at that time are shown in FIG. 33. As with the A50-18 strain (Reference Example) used as a positive control, hamsters infected with candidate strain 7 (Example) did not lose weight when infected with the SARS-CoV-2 B-1 strain. This result revealed that candidate strain 7 (Example) was able to induce immunity that contributes to infection protection, similar to the A50-18 strain (Reference Example).

[0124] [Test Example 13] Immunogenicity evaluation of candidate strains 2 and 5 at high titers and high doses (Example) Candidate strains 2 and 5 (Examples) were evaluated for immunogenicity in high titer and high dose experiments. 3 Or 1×10 420μL of the TCID50 candidate strain was administered intranasally. In addition, 1×10 of the SARS-CoV-2 temperature-sensitive strain A50-18 strain (reference example) was administered as a positive control. 3 The same dose of TCID50 was administered intranasally. After 3 weeks, partial blood samples were taken from the recovered hamsters, and the neutralizing activity of the obtained serum was evaluated. The neutralizing activity was measured in the same manner as in Test Example 3. The results are shown in FIG.

[0125] Candidate strain 2: 1 × 10 3 After administration of TCID50, 4 out of 5 mice were observed to have positive neutralizing antibodies, with a 1×10 4 When TCID50 was administered, a positive conversion of neutralizing antibodies was observed in all individuals. 3 When TCID50 was administered, serum neutralizing activity was confirmed in only one of five mice, but 1 × 10 4 By administering TCID50 of the virus, the induction of neutralizing antibodies was observed in 3 out of 5 mice. These results demonstrated that the vaccine candidate strain combining temperature-sensitive mutations with proliferation-reducing and other attenuating mutations was less immunogenic at the same dose compared to a strain with only temperature-sensitive mutations, but showed the immunogenicity required to induce neutralizing antibodies by increasing the dose. Furthermore, candidate strain 2 was found to have neutralizing activity in monkeys, indicating that it induces immunity.

[0126] [Test Example 14] Evaluation of growth of candidate strain 2 at various temperatures The clinical isolate (B-1 strain [Comparative Example]) and candidate strain 2 ([Example]) were infected into Vero cells (N=3) using a 6-well plate under the condition of MOI=0.01. The cells were cultured at 37°C or 32°C, and the respective culture supernatants were collected 0 to 5 dpi. The viral titers of the culture supernatants 0 to 5 dpi were measured in TCID50 / mL using Vero cells. The results are shown in FIG. 35.

[0127] FIG. 35 shows that candidate strain 2 ([Example]) grew at 32°C to the same extent as the clinically isolated strain (strain B-1 [Comparative Example]), but its growth rate at 37°C was significantly reduced.

[0128] [Test Example 15] Test on the persistence of humoral immunity induced by administration of candidate strain 2 (Example) Four-week-old male Syrian hamsters (n=10) were raised for one week and then incubated under anesthesia with candidate strain 2 (example) (1x10 3 TCID50 or 1x10 4 In the two-dose group, candidate strain 2 (1x10 TCID50) was administered intranasally at a dose of 20 μL. In the two-dose group, candidate strain 2 (1x10 3 TCID50 or 1x10 4 20 μL of TCID50 of the inactivated serum was administered intranasally. Partial blood samples were taken over time, and the serum was inactivated by heat treatment at 56°C for 30 minutes. 100 TCID50 of B-1 strain (D614G type: pre-alpha European strain) or TY38-873 strain (omicron variant) was mixed with serially diluted inactivated serum and reacted at 37°C for 1 hour. The culture solution after the reaction was inoculated onto Vero cells, and after incubation at 37°C, the virus neutralizing activity was evaluated by observing CPE. The lowest dilution rate at which CPE did not occur was defined as the neutralizing antibody titer. The results are shown in Figure 36.

[0129] As shown in Figure 36, a single administration of candidate strain 2 increased the serum neutralizing antibody titer to 6-12. Furthermore, when a second administration was performed 4 weeks after the first administration, no increase in neutralizing antibody titer was observed, suggesting that sufficient humoral immunity was induced by a single administration. Furthermore, the serum neutralizing antibody thus obtained did not decrease significantly even 4 months after administration. From these results, candidate strain 2 was found to be effective in the hamster model at a dose of 1x10 3 It was revealed that a single dose of TCID50 induced sufficient humoral immunity, and that this humoral immunity persisted for at least 4 months after administration. In addition, stimulating spleen cells from hamsters infected with candidate strain 2 with the spike antigen peptide induced the production of antigen-specific IFN-γ. These results demonstrated that administration of candidate strain 2 induced antigen-specific Th1 cells, and that candidate strain 2 also induced cellular immunity.

[0130] [Test Example 16] Infection protection test by administration of candidate strain 2 (Example) Test Example 13: 1×103 , 1×10 4 TCID50 of candidate strain 2 or 1 x 10 3 Hamsters were intranasally administered 20 μL of TCID50 of the temperature-sensitive SARS-CoV-2 A50-18 strain, and 3 weeks after the first administration, SARS-CoV-2 B-1 strain (3x10 5 A challenge test was carried out by intranasally administering 100 μL of TCID50 under anesthesia conditions. The body weight of the hamsters after the challenge test was measured up to 6 days after administration. The results are shown in FIG.

[0131] Figure 37 shows that hamsters infected with candidate strain 2 or the A50-18 strain did not lose weight when infected with the SARS-CoV-2 B-1 strain, and were able to induce immunity that contributes to protection against infection.

[0132] [Test Example 17] Study on reversion of virulence during in vivo passage of candidate strain 2 (Example) Four-week-old male Syrian hamsters (n=5) were raised for one week and then incubated under anesthesia with either the temperature-sensitive strain A50-18 or candidate strain 2 (1x10 5 The TCID50 was administered intranasally in a volume of 100 μL. This volume was calculated as a human equivalent volume using a divisor of 30 to extrapolate the no-adverse-effect dose in hamsters to the no-adverse-effect dose in humans, which is 2 × 10 5PFU / dose. The body weight change was observed, and the hamster was euthanized 3 days after administration, and nasal wash was collected using 500 μL of PBS. The obtained nasal wash was sterilized by filtration using a 0.22 μm filter, and 100 μL of the nasal wash was administered intranasally to the next generation of hamsters under anesthesia conditions. The same procedure was performed three times to obtain nasal washes after 1 to 4 in vivo passages. The obtained nasal wash was seeded on Vero cells and cultured at each temperature to evaluate the presence or absence of infectious virus and the temperature sensitivity of the virus. In addition, viral RNA was extracted from the nasal wash, and the base sequence of the target site was confirmed by Sanger sequencing. The presence or absence of CPE in Vero cells seeded with nasal wash after each passage is shown in Figure 38, the sequence confirmation results of viral RNA extracted from nasal wash after the fourth in vivo passage is shown in Figure 39, and the results of body weight change of the hamster at each in vivo passage are shown in Figure 40.

[0133] Since the A50-18 strain is a temperature-sensitive strain, it does not cause CPE when it is infected into Vero cells and then cultured at 37°C or 39°C. However, as shown in FIG. 38, it was observed that when nasal washes from hamsters infected with the A50-18 strain were added to Vero cells and cultured at 37°C or 39°C, CPE was caused. In addition, as shown in FIG. 39, the sequence of the viral RNA contained in the nasal washes after in vivo passage was confirmed, and it was revealed that the G416S and G248V mutations in NSP14, which are mutations that cause temperature sensitivity, were lost. Furthermore, as shown in FIG. 40, when the weight change of hamsters during in vivo passage was evaluated, it was observed that hamsters infected with nasal washes after in vivo passage of the A50-18 strain lost weight. These results suggested that the A50-18 strain may generate a virulence revertant strain that has lost temperature sensitivity by losing the mutation that causes temperature sensitivity in the hamster's body, and spread to other individuals.

[0134] On the other hand, in the case of candidate strain 2, as shown in FIG. 38, a virus showing temperature sensitivity was detected in the nasal wash after the first in vivo passage, while the virus was hardly detected in the nasal wash after the second or subsequent in vivo passage. In addition, as shown in FIG. 39, as a result of confirming the sequence of the viral RNA contained in the nasal wash after in vivo passage, some of the mutations that cause temperature sensitivity were lost (however, even in such passaged strains, only one of the combinations of mutations at positions 248 and 416 in NSP14 was lost). On the other hand, the partial deletion of NSP1 (growth-reducing mutation), the deletion of the furin cleavage site of the spike, and the deletion of ORF7a-8, which are mutations that cause attenuation, were maintained. Furthermore, as shown in FIG. 40, no weight loss was observed in hamsters infected with nasal wash after in vivo passage of candidate strain 2. These results suggest that candidate strain 2 is a candidate strain that is less likely to cause virulence reversion compared to the A50-18 strain, which has only mutations that cause temperature sensitivity. From these results, it can be inferred that the attenuated betacoronavirus strain of the present invention combines a specific temperature-sensitive mutation (substitution mutation) with a specific growth-reducing or other attenuating mutation (deletion mutation), thereby significantly improving its usefulness as a vaccine in that even when the virus is administered to humans as a live vaccine, there is a low possibility of the virus reverting to virulence being transmitted.

[0135] [Test Example 18] Evaluation of tissue damage caused by candidate strain 2 (Example) Four-week-old male Syrian hamsters (n=4) were raised for one week, and then, under anesthesia, SARS-CoV-2 B-1 strain [Comparative Example], temperature-sensitive strain A50-18 strain [Reference Example], or candidate strain 2 [Example] (1x10 5 The TCID50 was administered intranasally in a volume of 20 μL. This volume was calculated as a human equivalent volume using a divisor of 30 to extrapolate the no-adverse-effect dose in hamsters to the no-adverse-effect dose in humans, which is 4 × 10 4 The same dose of medium was administered intranasally to the non-infected group (naive) under anesthesia conditions. As a positive control, SARS-CoV-2 B-1 strain (1x10 5TCID50) was administered intranasally under anesthesia at a dose of 100 μL. The virus solution reached the upper respiratory tract of the hamsters when administered intranasally at a dose of 20 μL, and reached the lower respiratory tract of the hamsters when administered intranasally at a dose of 100 μL. Three days after administration, the animals were euthanized and their heads and lungs were fixed in formalin. Histopathology was evaluated by HE staining, and viral antigens were detected by IHC staining using rabbit anti-spike RBD antibody (Sinobiological (40592-T62)). The lesions in the nasal cavity and lungs of each individual and the score of viral antigen detection by IHC are shown in Table 6. In this table, Level 1 indicates the tip of the nasal cavity, Level 2 indicates the middle of the nasal cavity, and Level 3 indicates the back of the nasal cavity. Representative examples of each site of each virus-infected hamster are shown in Figure 41 for Level 1, Figure 42 for Level 2, Figure 43 for Level 3, and Figure 44 for the lungs.

[0136] 41 to 44, in the system administered with SARS-CoV-2 B-1 strain (Comparative Example), not only in the positive control in which the virus liquid was administered nasally to the lower respiratory tract, but also in the hamster in which the virus liquid was administered nasally to the upper respiratory tract, tissue damage and viral antigens were detected from the tip to the deep part of the nasal cavity and in the lungs. In the hamster in which the A50-18 strain (Reference Example) or the candidate strain 2 (Example) was administered nasally to the upper respiratory tract, mild tissue damage and viral antigens were detected only at the tip of the nasal cavity, while no tissue damage or viral antigens were detected in the deep part of the nasal cavity and the lungs. These results strongly suggest that the candidate strain 2 (Example) and the temperature-sensitive strain A50-18 strain (Reference Example) cause viral proliferation and associated tissue damage at the tip of the nasal cavity, which is close to the outside temperature, while the viral proliferation and associated tissue damage are suppressed in the deep part of the nasal cavity and the lungs, which are close to body temperature, and that the candidate strain 2 (Example) has a higher effect of suppressing viral proliferation and associated tissue damage, and furthermore, has a lower risk of olfactory impairment.

[0137] [Table 6]

[0138] [Test Example 19] Immunogenicity evaluation using candidate strain 2 (challenge test using heterologous strain) We evaluated whether the immunity induced by candidate strain 2 contributes to protection against infection with the SARS-CoV-2 omicron variant. Four-week-old male Syrian hamsters were kept for one week, and then infected with candidate strain 2 (1x10 3 PFU) was administered intranasally at a dose of 20 μL. Four weeks after administration, serum was collected by partial blood sampling. The obtained serum was inactivated by heat treatment at 56°C for 30 minutes. 100 TCID50 of B-1 strain (D614G type: pre-alpha European strain) or TY41-702 strain (Omicron variant: BA.5) was mixed with serially diluted inactivated serum and reacted at 37°C for 1 hour. The culture solution after the reaction was inoculated onto Vero cells, and after incubation at 37°C, the virus neutralizing activity was evaluated by observing CPE. The lowest dilution ratio that did not cause CPE was taken as the neutralizing antibody titer. The results are shown in Figure 45. In addition, 4 weeks after administration, TY41-702 strain (3x10 5 A challenge test was performed by intranasally administering 100 μL of 10 ...

[0139] As shown in Figure 45, the results of measuring the neutralizing antibody titer revealed that administration of candidate strain 2 induced not only neutralizing antibodies against the B-1 strain, but also neutralizing antibodies against omicron variant BA.5 to a certain extent. Furthermore, when a challenge test with omicron variant BA.5 was performed on hamsters administered with candidate strain 2, a tendency for weight recovery to be faster than that of naive hamsters was observed as shown in Figure 46. Furthermore, the results of quantifying the amount of virus in the lungs and nasal lavage fluid 4 days after infection suggested that the amount of virus in the body of hamsters administered with candidate strain 2 was smaller than that of naive hamsters.

[0140] [Test Example 20] Immunogenicity evaluation using candidate strain 2 (neutralizing activity evaluation using heterologous strains) We evaluated whether the immunity induced by candidate strain 2 is effective against SARS-CoV-2 delta variants and gamma variants. The neutralizing activity of the candidate strain 2 immune serum obtained in Test Example 13 against gamma variants and delta variants was measured. 100 TCID50 of BK325 strain (delta variant) or TY7-501 strain (gamma variant) was mixed with serially diluted inactivated serum and reacted at 37°C for 1 hour. The culture solution after the reaction was inoculated onto Vero cells, and after incubation at 37°C, the virus neutralizing activity was evaluated by observing CPE. The lowest dilution ratio that did not cause CPE was taken as the neutralizing antibody titer. The results are shown in Figure 47 alongside the neutralizing activity evaluation against the wild-type strain in Test Example 13. In Figure 47, Low is 1 x 10 3 The results are from intranasal administration of 20 μL of the TCID50 candidate strain. The high level is 1 × 10 4 This is the result of intranasal administration of 20 μL of the TCID50 candidate strain.

[0141] As shown in Figure 47, the immunity induced by candidate strain 2 exhibited neutralizing activity against gamma variants and delta variants, and was shown to be effective. These results suggest that the immunity induced by administration of candidate strain 2 is also effective against heterozygous variants.

Claims

1. A nonstructural protein having a temperature-sensitive mutation selected from three types of mutations or combinations of mutations: a mutation in (b), a combination of mutations in (e) and (f), and a mutation in (h); A structural protein, an accessory protein, and a non-structural protein having the following mutations (g), (n), (o), (p), (q), and (r); Including, An attenuated SARS-CoV-2 virus strain, wherein the temperature-sensitive mutation consists only of a combination of the mutations (e) and (f): (b) a mutation in NSP3 at the amino acid residue corresponding to leucine at position 445 of the amino acid sequence set forth in SEQ ID NO:1; (e) a mutation in NSP14 of the amino acid residue corresponding to glycine at position 248 of the amino acid sequence set forth in SEQ ID NO:2 to valine; (f) a mutation in NSP14 of the amino acid residue corresponding to glycine at position 416 of the amino acid sequence set forth in SEQ ID NO:2 to serine; (g) a mutation in NSP14 of the amino acid residue corresponding to alanine at position 504 of the amino acid sequence set forth in SEQ ID NO:2 to valine; (h) a mutation in NSP16 at the amino acid residue corresponding to valine at position 67 of the amino acid sequence set forth in SEQ ID NO:3; (n) a loss-of-function mutation of ORF8; (o) a deletion in the spike of an amino acid sequence corresponding to positions 681 to 684 of the amino acid sequence shown in SEQ ID NO: 4; (p) a mutation in spike comprising a deletion of the amino acid sequence corresponding to positions 679 to 680 and 685 to 686 of the amino acid sequence shown in SEQ ID NO: 4; (q) a mutation in spike of the amino acid residue corresponding to valine at position 687 of the amino acid sequence shown in SEQ ID NO: 4 to isoleucine; (r) A deletion in NSP1 of the amino acid sequence corresponding to positions 32 to 39 of the amino acid sequence set forth in SEQ ID NO:

8.

2. The attenuated strain of SARS-CoV-2 virus according to claim 1, wherein the mutation (n) is a deletion of an amino acid sequence corresponding to the amino acid sequence encoded by the base sequence shown in SEQ ID NO:

7.

3. A live attenuated vaccine comprising the attenuated strain of SARS-CoV-2 virus of claim 1.

4. The live attenuated vaccine of claim 3, which is administered intranasally.

Citation Information

Patent Citations

  • Beta coronavirus cold acclimatized strain and vaccine

    WO2022080413A1

  • Temperature-sensitive betacoronavirus strain and vaccine

    WO2022080414A1